Received prior radiotherapy to any portion of the abdominal cavity or pelvisXx_NEWLINE_xXReceived radiotherapy to metastatic sites of disease <2 weeks prior to Day 1.Xx_NEWLINE_xXPrior selective internal radiotherapy/hepatic arterial yttrium therapy, at any timeXx_NEWLINE_xXPrevious therapy with at least radiotherapy and temozolomideXx_NEWLINE_xXMust be 12 weeks from radiotherapy; if patients are within 12 weeks of radiotherapy, then the progressive lesion must be outside of the high-dose radiation target volume or have unequivocal evidence of progressive tumor on a biopsy specimenXx_NEWLINE_xXPrior radiotherapy is allowed if more than 14 days have elapsed since the end of treatmentXx_NEWLINE_xXPrior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is allowed but the subject must have either histopathologic confirmation of recurrent tumor, or new enhancement on MRI outside of the radiotherapy treatment fieldXx_NEWLINE_xXPatients who have received prior pelvic radiotherapyXx_NEWLINE_xXSuitable for breast conserving surgery and radiotherapyXx_NEWLINE_xXRadiotherapy may be given before or after protocol treatment per standard of care guidelines; when radiotherapy is planned prior to protocol treatment administration, patients may be registered and screened while receiving radiation\r\n* Post-mastectomy radiotherapy is required for all patients with the following:\r\n** Primary tumor >= 5 cm (prior to neoadjuvant chemotherapy [clinically] or at the time of definitive surgery) or involvement of lymph nodes at the time of definitive surgery\r\n** For patients with primary tumors < 5 cm or without lymph node involvement prior to neoadjuvant chemotherapy and at the time of definitive surgery, provision of post-mastectomy radiotherapy is at the discretion of the treating physician\r\n** Radiation of regional nodal basins is at the discretion of the treating radiation oncologist\r\n* NOTE: Breast radiotherapy (whole breast or partial) is required for patients who underwent breast-conserving therapy, including lumpectomy or partial mastectomyXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Radiotherapy may be given before or after protocol treatment. when radiotherapy is planned prior to protocol treatment administration, patients must have completed adjuvant radiotherapy >= 2 weeks prior to randomization for protocol therapy, if applicableXx_NEWLINE_xXNo prior mediastinal or thoracic radiotherapyXx_NEWLINE_xXPatients receiving adjuvant radiotherapy within 2 weeks prior to randomizationXx_NEWLINE_xXPrior radiotherapy to the abdomen or pelvisXx_NEWLINE_xXPatients with active HCV infection should be referred for HCV treatment and standard radiotherapy for the plasmacytomaXx_NEWLINE_xXNo prior radiotherapy or chemotherapy, with the exception of dexamethasone, which is allowedXx_NEWLINE_xXPatients must have no previous radiotherapy or chemotherapy other than corticosteroidsXx_NEWLINE_xXSubjects may receive palliative radiotherapy for symptomatic metastases prior to enrollment provided that there is at least one other non-irradiated lesion amenable to LCT at the time of enrollment.Xx_NEWLINE_xXPatients who received breast/axilla/post-mastectomy chest wall radiotherapy must be after last dose of radiotherapy and must have sufficient resolution of side effects.Xx_NEWLINE_xXSubject has failed or intolerant to radiotherapy.Xx_NEWLINE_xXPatients may have received prior radiotherapyXx_NEWLINE_xXAny other radiotherapy or radionuclide require 28-day washout prior to first dose of study drugXx_NEWLINE_xXRadiotherapy with a wide field of radiation within 4 weeks,Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks prior to starting radiation treatmentXx_NEWLINE_xXPatients who have had any prior radiotherapy to the treatment site(s)Xx_NEWLINE_xXA patient may not participate in a concurrent treatment protocol; all patients will be eligible to receive chemotherapy alone, systemic therapeutic agents, or conventional chemo-radiotherapy at the time of clinical or radiographic disease progression or at 2 weeks following completion of SBRTXx_NEWLINE_xXFor participants treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, two weeks must have lapsed since last date of radiotherapy, which is recommended to be a limited field; participants who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed and two weeks have passed since the last date of therapyXx_NEWLINE_xXPatients must have failed prior radiation therapy and must have an interval of greater than or equal to 42 days from the completion of radiation therapy to study entry; Note: patients with an indication for craniospinal radiotherapy (i.e., extensive leptomeningeal disease) but have refused palliative craniospinal radiotherapy are eligibleXx_NEWLINE_xXPrior cranial or spinal radiotherapyXx_NEWLINE_xXPrior bladder-directed radiotherapy.Xx_NEWLINE_xXPrior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permittedXx_NEWLINE_xXRadiotherapy </= 28 days of enrollment. Patients must be recovered from all acute radiotherapy-related toxicities. No radiopharmaceuticals (strontium, samarium) within 8 weeks of enrollmentXx_NEWLINE_xXCohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Prior radiotherapy;\r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= 14 days prior to first dose of study treatment and not be experiencing > grade 1 treatment related toxicitiesXx_NEWLINE_xXCohort A Dose Expansion (Ribociclib + PDR001): Prior radiotherapy: \r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= 14 days prior to first dose of study treatment and not be experiencing grade > 1 treatment-related toxicitiesXx_NEWLINE_xXExpansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Prior radiotherapy:\r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= 14 days prior to first dose of study treatment and not be experiencing grade > 1 treatment-related toxicitiesXx_NEWLINE_xXParticipants who have received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowedXx_NEWLINE_xXHas cSCC that is amenable to surgical resection, local control with radiotherapy, or local control with a combination of surgery and radiotherapy, or chemoradiotherapy.Xx_NEWLINE_xXHas received prior radiotherapy within 2 weeks of start of study treatment.Xx_NEWLINE_xXConcurrent anticancer treatment within 28 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone directed radiotherapy]; immune therapy, or cytokine therapy, except for erythropoietin.Xx_NEWLINE_xXPrior palliative radiotherapy must have been completed at least 2 weeks prior to study entryXx_NEWLINE_xXSystemic antineoplastic therapy or radiotherapy within 14 days before the first dose of any study drugXx_NEWLINE_xXPalliative radiotherapy within 14 days before initiation of study treatmentXx_NEWLINE_xXPrior surgery or radiotherapy within 14 days of initiating therapy. Patients must have recovered from all radiation-related toxicities, and not required corticosteroids.Xx_NEWLINE_xXPatients cannot have received radiotherapy to lung fields within 6 months of study treatment start.Xx_NEWLINE_xXPatient has received chemotherapy or radiotherapy within 4 weeks prior to day 1 of study; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been radiatedXx_NEWLINE_xXPatients with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e. D1 of cycle 1); however, prior surgery or radiation therapy aimed at local palliation or attempted local disease control (except in case of thoracic radiotherapy) is permitted but has to be completed one week before treatment startXx_NEWLINE_xXRadiotherapy, unless documented contraindicationXx_NEWLINE_xXRadiotherapy within 2 weeks of first dose of study drugXx_NEWLINE_xXPatients for whom surgery would be deemed appropriate rather than radiotherapyXx_NEWLINE_xXChemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed four (4) weeks prior to first dose of study drug or without complete recovery from all such treatments.Xx_NEWLINE_xXRadiotherapy within 14 days before enrollmentXx_NEWLINE_xXChemotherapy or stereotactic radiotherapy within the last 2 weeksXx_NEWLINE_xXLess than four weeks since last radiotherapy (excluding palliative radiotherapy).Xx_NEWLINE_xXRadiotherapy within one week prior to starting study treatment.Xx_NEWLINE_xXRadiotherapy within 28 days prior to baseline.Xx_NEWLINE_xXPatients who received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within 4 weeks prior to registration are not eligibleXx_NEWLINE_xXWashout time of at least 4 weeks for prior biological, chemotherapeutic, or radiotherapyXx_NEWLINE_xXPrior radiotherapy to the target area.Xx_NEWLINE_xXPatients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapyXx_NEWLINE_xXHave brain metastasis without prior radiotherapy.Xx_NEWLINE_xXPatients who have received prior radiotherapy to all areas of current active disease are ineligibleXx_NEWLINE_xXRadiotherapy to multiple sites or immunotherapy within 3 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)Xx_NEWLINE_xXPrevious chemotherapy/radiotherapy/targeted therapy should have been completed at least 4 weeks prior to start of FID-007 administrationXx_NEWLINE_xXHas received prior radiotherapy within 2 weeks of start of trial treatment.Xx_NEWLINE_xXHave a history of prior radiotherapy to the whole pelvis.Xx_NEWLINE_xXHas received prior radiotherapy within 2 weeks of start of study therapyXx_NEWLINE_xXPrior radiotherapy within 2 weeks of the first dose of study treatmentXx_NEWLINE_xXHas received prior radiotherapy within 2 weeks of start of study treatment.Xx_NEWLINE_xXRadiotherapy: 6 weeksXx_NEWLINE_xXPrior radiotherapy is acceptable provided the patient has recovered from any radiotherapy related acute toxicities.Xx_NEWLINE_xXPrior radiotherapy is acceptable provided it was applied within 4 four weeks before starting of this trial and the patient recovered from any radiotherapy related acute toxicities.Xx_NEWLINE_xXPHASE II INCLUSION CRITERIA: For patients who do not receive radiotherapy after chemotherapy, the randomization must occur within 6 weeks of the last chemotherapy cycle; the study treatment must start within 2 weeks from randomization; for patients who receive radiotherapy (including prophylactic cranial radiation and/or thoracic radiation) after chemotherapy, the randomization must occur within 9 weeks of the last chemotherapy cycle but at least 2 weeks after completion of radiotherapy and the first dose of 177Lu-DOTA0-Tyr3-octreotate cannot be given within 8 weeks of radiotherapyXx_NEWLINE_xXHas received prior radiotherapy within 2 weeks of therapy.Xx_NEWLINE_xXRadiotherapy administered less than 21 days prior to the first dose of the IMP, or localized palliative radiotherapy administered less than 7 days prior to the first dose of the IMP, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 4.03.Xx_NEWLINE_xXPrior radiation therapy within 21 days prior to the start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment startXx_NEWLINE_xXPrior history of external beam radiotherapy >= 5,000 cGy delivered to the tumor at least 4 weeks prior to Office for Human Research Studies (OHRS) registrationXx_NEWLINE_xXChemotherapy or limited field radiotherapy within 2 weeks, wide field radiotherapy within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks prior to entering the studyXx_NEWLINE_xXParticipants who have had radiotherapy within 3 weeksXx_NEWLINE_xXPrior focal radiotherapy completed at least 4 weeks prior to study drug administration.Xx_NEWLINE_xXPrior radiotherapy or radiosurgery < 2 weeks prior to starting study treatmentXx_NEWLINE_xXPrior radiotherapy to the ipsilateral chest wall or ipsilateral breast or thorax; individuals with prior radiotherapy in the contralateral breast or chest wall are eligibleXx_NEWLINE_xXRadiotherapy: >=2 weeks must have elapsed since local palliative radiotherapy (XRT) (small port); >=3 months must have elapsed if prior Traumatic Brain Injury (TBI), craniospinal XRT or if >=50% radiation of pelvis; >=6 weeks must have elapsed if other substantial bone marrow irradiation was given.Xx_NEWLINE_xXCompleted pre-operative chemo radiotherapy followed by surgeryXx_NEWLINE_xXPatients who have had radiotherapy within 4 weeksXx_NEWLINE_xXPatients who have received radiation therapy within 3 weeks before transplant. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.Xx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPrior radiotherapy within 2 weeks of start of study treatmentXx_NEWLINE_xXRadiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited fieldXx_NEWLINE_xXRefractory (no prior CR/CMR) or relapsed (prior CMR) following front line treatment of standard multiagent chemotherapy containing an anthracycline AND an approved anti-CD20 agent. For subjects with refractory disease and who have received radiotherapy, PET positivity should be demonstrated no less than 6 weeks after the last dose of radiotherapyXx_NEWLINE_xXTraumatic injury or palliative radiotherapy within 2 weeks prior study treatment initiationXx_NEWLINE_xXHave not been treated with chemotherapy, biological therapy or breast radiotherapyXx_NEWLINE_xXPrior pelvic radiotherapy or prostatectomyXx_NEWLINE_xXRecurrent malignant gliomas previously treated with radiotherapy and/or chemotherapyXx_NEWLINE_xXPatients with HGG: Have previously received radiotherapy and temozolomide with a maximum of 2 prior relapses on treatmentXx_NEWLINE_xXPrior radiation to the primary and/or regional radiotherapy for melanoma and/or NSCLC is acceptableXx_NEWLINE_xXPrior thoracic radiotherapyXx_NEWLINE_xXMedical contraindication to receipt of radiotherapyXx_NEWLINE_xXCompleted palliative radiotherapy within 7 days of the first dose of study drug.Xx_NEWLINE_xXRadiotherapy within 14 days before enrollment; if the involved field covered =< 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapyXx_NEWLINE_xXPrior radiotherapy to the upper abdomenXx_NEWLINE_xXThoracic radiotherapy to lung fields =< 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting INC280 is allowedXx_NEWLINE_xXRadiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXAny major surgical procedures or external beam radiotherapy within 14 days prior to study drug administrationXx_NEWLINE_xXRadiotherapy delivered to non-target lesions within one week prior to starting study treatment or delivered to target lesions that will be followed on the study (note: prior sites of radiation will be recorded).Xx_NEWLINE_xXPatients must be registered on study no earlier than 7 days and no later than 56 days prior to Step 1 registration after completing chemotherapy, Note:\r\n* Post-chemotherapy restaging imaging must be completed no earlier than 56 days prior to Step 1 registration\r\n• For patients with limited-stage small cell lung cancer who receive thoracic radiotherapy concomitant with chemotherapy, patients must be registered on study no earlier than 7 days and no later than 56 days prior to Step 1 registration after completing thoracic radiotherapy\r\n• For patients with extensive-stage small cell lung cancer who are being considered for consolidative thoracic radiotherapy after chemotherapy, concomitant administration of consolidative thoracic radiotherapy and protocol-specified prophylactic cranial irradiation with or without hippocampal avoidance is permitted; if consolidative thoracic radiotherapy is performed prior to study registration, then patients must be registered on study no earlier than 7 days and no later than 56 days prior to Step 1 registration after completing thoracic radiotherapyXx_NEWLINE_xXPatients who have received radiotherapy =< 2 weeks prior to starting study drugs, with exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =< 1 and/or from whom >= 30% of the bone marrow was irradiatedXx_NEWLINE_xXPatient may have prior salvage therapy (surgery, radiation or other local ablative procedures) within 6 months prior to randomization if the intent was for cure; prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to randomization is allowedXx_NEWLINE_xXRadiation therapy within prior 6 months (prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to randomization is allowed)Xx_NEWLINE_xXPatients who have had any prior bevacizumab, due to case reports suggesting a possible risk of severe toxicity in combination with radiotherapyXx_NEWLINE_xXRadiotherapy: at least 3 weeks since most recent radiotherapy; prior radiated lesions will not be evaluable unless there is documented progression post therapy; palliative radiotherapy to localized painful lesions is acceptable when the patient is on study: at least one week after completion of radiation therapy (RT) and recovery from associated toxicities before restarting ARQ 761; irradiated lesions will not be evaluable for responseXx_NEWLINE_xXRadiotherapy or chemotherapy within the 14 days prior to the first dose of BGB324 being administered (other than hydroxyurea)Xx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patients must have received prior radiotherapy and/or chemotherapy with the following exceptions:\r\n* Patients with secondary CNS cancers after a previous medical problem/malignancy who cannot receive full dose of radiotherapy (> 50 Gy) as long as they meet all other eligibility criteria\r\n* Patients with progressive low-grade gliomas and CMMRD or Lynch syndrome\r\nPatients must have recovered from the acute treatment related toxicities (defined as =< grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study; there is no upper limit to the number of prior therapies that is allowedXx_NEWLINE_xXRadiotherapy within the last 4 weeks before start of study drug treatment with the exception of limited field palliative radiotherapy for bone pain reliefXx_NEWLINE_xXRadiotherapy within 14 days before randomization.Xx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXPatients must not have had standard of care chemotherapy, radiotherapy, or major surgery within the last 2 weeks prior to entering the study; Note: local surgeries for isolated lesions for palliative intent are acceptable; for recent experimental therapies a 28 day period of time must have elapsed before commencing protocol treatmentXx_NEWLINE_xXPossibility of a curative local treatment (surgery and/or radiotherapy)Xx_NEWLINE_xXRadiotherapy: patients must have had their last fraction of: \r\n* Focal irradiation > 2 weeks prior to enrollmentXx_NEWLINE_xXRadiotherapy within 14 days before enrollment; radiotherapy is excluded during induction and consolidation 1 while receiving MLN 9708Xx_NEWLINE_xXMust have discontinued radiotherapy at least 14 days with resolution of any toxicity to Grade 1 or better prior to the start of treatment.Xx_NEWLINE_xXPatients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.Xx_NEWLINE_xXNo prior chemotherapy or thoracic radiotherapy for lung cancerXx_NEWLINE_xXRadiotherapy =< 14 days prior to enrollment; patients must have recovered from all radiotherapy-related toxicitiesXx_NEWLINE_xXPrior radiotherapy to thoracic area.Xx_NEWLINE_xXPatients who have had radiotherapy =< 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicitiesXx_NEWLINE_xXChemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drugXx_NEWLINE_xXradiotherapy within 4 weeks prior to treatment with APS001F (intensive radiotherapy within 6 weeks or palliative radiotherapy within 2 weeks).Xx_NEWLINE_xXContraindication to receiving radiotherapyXx_NEWLINE_xXReceived external beam radiotherapy within the 4 weeks prior to randomizationXx_NEWLINE_xXHas an immediate need for external beam radiotherapyXx_NEWLINE_xXPatients who have completed focal radiotherapy within 14 weeks from time of enrollment are eligible.Xx_NEWLINE_xXPrior radiation: Patients must have received prior treatment with focal radiotherapy as part of initial treatment for DIPG and had their last dose at least 4 weeks prior to and no later than 14 weeks from the first CED treatment. Standard focal radiation therapy will include 54 to 60 Gy by external beam radiotherapy to the brainstem.Xx_NEWLINE_xXPatients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatmentXx_NEWLINE_xXIs eligible for palliative radiotherapy as determined by the treating radiation oncologist.Xx_NEWLINE_xXAnticancer treatment within 14 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).Xx_NEWLINE_xXPrior therapy is allowed provided the following are met: at least 4 weeks since prior locoregional therapy including surgical resection, chemoembolization, radiotherapy, or ablation. Provided target lesion has increased in size by 25% or more or the target lesion was not treated with locoregional therapy. Patients treated with palliative radiotherapy for symptoms will be eligible 1 week after treatment as long as the target lesion is not the treated lesionXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks prior to study entry. Palliative radiotherapy for symptomatic control is acceptable (if completed at least 2 weeks prior to study drug administration and no additional radiotherapy for the same lesion is planned)Xx_NEWLINE_xXPrior whole brain radiotherapy.Xx_NEWLINE_xXPrevious first line treatment with at least radiotherapy.Xx_NEWLINE_xXNo prior chemotherapy, immunotherapy, or targeted therapy for the treatment of CLL with the exception of palliative loco-regional radiotherapy and corticosteroids for symptom controlXx_NEWLINE_xXLesion that is amenable to palliative radiotherapyXx_NEWLINE_xXPrior systemic treatment of any kind or radiotherapy for RCCXx_NEWLINE_xXThe metastases have been treated by surgery and/or radiotherapy.Xx_NEWLINE_xXRequires prohibited treatment (i.e., non-protocol specified anticancer pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor). Limited field single dose radiotherapy for pain palliation would be allowed.Xx_NEWLINE_xXAnticancer treatment within 14 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).Xx_NEWLINE_xXPrior radiotherapy =< 14 daysXx_NEWLINE_xXPatients must be 4 weeks beyond previous treatment of any chemotherapy or radiotherapy, and must have recovered to =< grade 1 or previous baseline for each toxicity. Exception: Patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field. Patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents.Xx_NEWLINE_xXThe patient will receive thoracic stereotactic body radiotherapy at MD Anderson.Xx_NEWLINE_xXPrevious pelvic radiotherapyXx_NEWLINE_xXRadiotherapy: ?4 weeks (patients who receive palliative radiation for nontarget tumour lesions need not be subjected to this washout period and can be enrolled immediately)Xx_NEWLINE_xXPrior palliative radiotherapy to non-central nervous system (CNS) lesions must have been completed at least 2 weeks prior to treatment; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of first treatment are strongly encouraged to receive palliative radiotherapy prior to treatmentXx_NEWLINE_xXSubject must refuse or not be eligible for radiotherapy.Xx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients who have undergone radiotherapy within 4 weeks of first dose of study treatmentXx_NEWLINE_xXHas received prior radiotherapy for RCC.Xx_NEWLINE_xXTreatment with radiotherapy/radiopharmaceuticals within 2 weeks before randomization.Xx_NEWLINE_xXRadiotherapy within 2 weeks of first dose of study medicationsXx_NEWLINE_xXRadiotherapy (except for brain and extremities or stereotactic treatment) within the past 2 weeks prior to treatment with the trial drugXx_NEWLINE_xXRadiotherapy to a target lesion within the past 3 months prior to baseline imaging unless that area has demonstrated progressionXx_NEWLINE_xXPatients requiring palliative radiotherapy to lesions that are defined as target lesions by RECIST criteria at the time of study entry.Xx_NEWLINE_xXAny prior radiotherapy to the lungXx_NEWLINE_xXContraindication to receive radiotherapyXx_NEWLINE_xXPrior use of chemotherapy, radiotherapy, and / or investigational agents for pancreatic cancerXx_NEWLINE_xXAny prior radiotherapy to the neckXx_NEWLINE_xXRadiotherapy to target lesions during study or within 2 weeks of enrollmentXx_NEWLINE_xXPatients may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed per the following timelines:\r\n* Radiotherapy to the thoracic cavity or abdomen within 4 weeks prior to registration\r\n* Radiotherapy to bone lesions within 2 weeks prior to registration\r\n* Radiotherapy to any other site within 4 weeks prior to registration\r\n* NOTE: In all cases, there must be complete recovery and no ongoing complications from prior radiotherapyXx_NEWLINE_xXPrior mediastinal radiotherapyXx_NEWLINE_xXHas received prior approved radiotherapy within 14 days of study therapy.Xx_NEWLINE_xXPrior treatment: chemotherapy or radiotherapy or surgeryXx_NEWLINE_xXPatients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapyXx_NEWLINE_xXNo prior cytotoxic chemotherapy; prior therapy with single-agent rituximab is permitted; prior involved-field radiotherapy to symptomatic nodal sites of involvement is also permittedXx_NEWLINE_xXPatients who have had radiotherapy within < 4 weeks are ineligibleXx_NEWLINE_xXInterval of at least 8 weeks from the completion of radiotherapy; if patients are within 8 weeks of radiotherapy, they may still be eligible if they meet one or more of the following criteria\r\n* Progressive tumor is outside the original high-dose radiotherapy target volume as determined by the treating investigator, or\r\n* Histologic confirmation of tumor through biopsy or resection, or\r\n* Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than pseudoprogression or radiation necrosis obtained within 28 days of registrationXx_NEWLINE_xXPatient must be selected for standard temozolomide chemotherapy to be administered with radiotherapyXx_NEWLINE_xXSubjects who had major surgery or radiation therapy within 4 weeks of the first dose of study drug, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass.Xx_NEWLINE_xXHave received prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation.Xx_NEWLINE_xXPatients who have had any prior chemotherapy or radiotherapy for prostate cancer.Xx_NEWLINE_xXHas received chemotherapy or radiotherapy within 14 days of first dose of study medicationXx_NEWLINE_xXBiochemical recurrence within one year of completion of radiotherapyXx_NEWLINE_xXConventional or stereotactic pituitary radiotherapy any time in the pastXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXMore than one prior course of radiotherapy or prior prescription doses exceeding 60 Gy to target volumesXx_NEWLINE_xXPatient has received any pelvic radiotherapy (including external beam and/or brachytherapy).Xx_NEWLINE_xXDispositioned to single modality photon radiotherapy (i.e. no chemotherapy or previous therapeutic intent surgery).Xx_NEWLINE_xXPatients who have had radiotherapy within the last 4 weeks before the first OBP-301 administration.Xx_NEWLINE_xXPrior chest radiotherapy ? 3 months, wide field radiotherapy ? 28 days (defined as > 50% of volume of pelvic bones or equivalent), or limited field radiation for palliation ? 14 days prior to study treatment - Such patients must have recovered adequately from any side effects of such therapy.Xx_NEWLINE_xXPatients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment initiationXx_NEWLINE_xXNo chemotherapy or radiotherapy within the past 28 daysXx_NEWLINE_xXDisease that can be encompassed within a radical radiotherapy treatment volumeXx_NEWLINE_xXPatients must not have had chemotherapy =< 28 days or radiotherapy =< 7 days prior to study treatmentXx_NEWLINE_xXNo prior breast or thoracic radiotherapyXx_NEWLINE_xXSubjects must not have prior breast or thoracic radiotherapyXx_NEWLINE_xXSubjects must not have received or plan to receive neoadjuvant chemotherapy either before radiotherapy or before surgeryXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks of first dose of zydeligXx_NEWLINE_xXAbility to undergo potentially curative chemotherapy plus radiotherapyXx_NEWLINE_xXPrevious chest radiotherapyXx_NEWLINE_xXPrior radiotherapy to the ipsilateral chest wall or breast for any malignancyXx_NEWLINE_xXKnown contraindications to radiotherapyXx_NEWLINE_xXNo prior chemotherapy or radiotherapy for NSCLCXx_NEWLINE_xXResidual areas of limited disease should be considered for radiotherapy after and not prior to transplantationXx_NEWLINE_xXRadiotherapy within 2 weeks before the start of protocol-specified therapy.Xx_NEWLINE_xXPrior palliative radiotherapy must have been completed at least 2 weeks prior to registration; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to randomizationXx_NEWLINE_xXPatients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the studyXx_NEWLINE_xXPatients are known to have contraindications to radiotherapyXx_NEWLINE_xXPatients who have had previous radiotherapy in the thoraxXx_NEWLINE_xXNo radiotherapy within 2 weeksXx_NEWLINE_xXPatient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy­related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy­related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowedXx_NEWLINE_xXPatients must have received prior treatment with focal radiotherapy as part of initial treatment for DIPG and had their last dose at least 4 weeks prior to and no later than 14 weeks from the first CED treatment with liposomal irinotecan; standard focal radiation therapy will include 54 to 60 Gy by external beam radiotherapy to the brainstemXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 21 days of enrollmentXx_NEWLINE_xXPatient has received chemotherapy or radiotherapy within 4 weeks prior to day 1 of study; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been radiatedXx_NEWLINE_xXHas received any pelvic radiotherapy (including external beam and/or brachytherapy.)Xx_NEWLINE_xXAny prior radiotherapy or chemotherapy for pancreatic cancerXx_NEWLINE_xXPrior radiotherapy to the region of the study cancer that would result in overlap of radiation fieldsXx_NEWLINE_xXPatients may not have had prior radiotherapy (> 30 Gy) to the area requiring treatment that would result in any overlap of tissue in both fieldsXx_NEWLINE_xXPatient who has had any prior radiotherapy to the treatment site(s)Xx_NEWLINE_xXPrior radiation that precludes delivery of hypofractionated radiotherapyXx_NEWLINE_xXPrior peptide-receptor radiotherapy (PRRT)Xx_NEWLINE_xXPrior radiotherapy to the mediastinal/pericardial regionXx_NEWLINE_xXParticipants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last 4 weeksXx_NEWLINE_xXPrior cytotoxic chemotherapy or radiotherapy for this lymphomaXx_NEWLINE_xXSalvage therapy that includes involved field radiotherapyXx_NEWLINE_xXHistory of receiving chemotherapy or radiotherapyXx_NEWLINE_xXCompletion of any prior radiotherapy (Cohort C)Xx_NEWLINE_xXRadiotherapy for RCC within 14 days of first study treatment with the exception of a single fraction of radiation administered for palliation of symptomsXx_NEWLINE_xXPrevious first line therapy with at least radiotherapyXx_NEWLINE_xXPatients must be >= 4 weeks beyond previous treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field; patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agentsXx_NEWLINE_xXAt least 4 weeks from prior chemotherapy, radiotherapy or immunotherapy, or prior investigational agentsXx_NEWLINE_xXPrior selective internal radiotherapy/hepatic arterial yttrium therapy, at any timeXx_NEWLINE_xXPrior radiotherapy or gamma knife within 2 weeks of study treatment for non-brain metastasis; subjects must have recovered from all radiation related toxicitiesXx_NEWLINE_xXPrior radiotherapy or gamma knife within 2 weeks of study treatment for non-brain metastasis; subjects must have recovered from all radiation related toxicitiesXx_NEWLINE_xXRadiotherapy completed within 2 weeks prior to treatment initiation; radiotherapy completed > 2 weeks prior to treatment initiation is allowed if all procedure-related toxicities resolvedXx_NEWLINE_xXParticipants in cohort D must have completed systemic therapy AND have completed either consolidation thoracic radiotherapy or PCI or both completed either consolidation thoracic radiotherapy or PCI or both; participants in cohort D must initiate therapy with pembrolizumab within 6 weeks of the last dose of radiation; therapy must not start within 2 weeks from the last dose; consolidation radiotherapy dose must NOT be more than 3000 cGy; participants in cohort D must not have had progression of disease prior to the start of therapyXx_NEWLINE_xXRadiotherapy =< 14 days prior to registrationXx_NEWLINE_xXPersistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapyXx_NEWLINE_xXMust have previously untreated lymphoma; a short (< 2 week) course of steroids for symptom palliation is permitted; prior involved field radiotherapy for symptom palliation is permitted as long as there is measurable disease outside the radiation port; if radiotherapy has been given, there should be at least 7 days between last treatment and beginning of protocol therapyXx_NEWLINE_xXPatients must not have had chemotherapy or radiotherapy =< 28 days prior to study registrationXx_NEWLINE_xXPrevious extensive radiotherapy to the lung or liver during the last 4 months prior to lymphodepletion regimen.Xx_NEWLINE_xXPatients who have had prior abdominal radiotherapyXx_NEWLINE_xXRadiotherapy for primary HPVOC within 8 weeks, or radiotherapy for any other reason within 3 weeks prior to the first dose of vaccineXx_NEWLINE_xXPatients may not receive other concurrent investigational agent, chemotherapy, radiotherapy, or immunotherapy for CLL; NOTE: Localized radiotherapy to an area not compromising bone marrow function does not applyXx_NEWLINE_xXPatients who have had radiotherapy ? 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicitiesXx_NEWLINE_xXAt least 21 days have passed since completing radiotherapy (exception for radiotherapy: at least 7 days since completing a single fraction of =< 800 cGy to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit) at the time of registrationXx_NEWLINE_xXLess than 21 days between registration and the last receipt of chemotherapy, biotherapy, immunotherapy, radiotherapy (excluding palliative radiotherapy), or major surgery; prior receipt of immunomodulatory therapy (eg: nivolumab) is permitted, as long as there has been a 21 day washout period following the most recent treatmentXx_NEWLINE_xXPatients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study; for recent experimental therapies a 28 day period of time must elapse before treatmentXx_NEWLINE_xXPrevious radiotherapy within 3 months before study entryXx_NEWLINE_xXPrior radiotherapy completed <28 days before study enrollment.Xx_NEWLINE_xXPatients treated with previous cranial or head/neck radiotherapy leading to radiation field overlapXx_NEWLINE_xXPrior whole brain radiotherapy or conventional external beam radiotherapyXx_NEWLINE_xXPatients who have had previous chemotherapy or radiotherapy for pancreatic adenocarcinoma prior to entering the studyXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPrior cranial radiotherapy within 90 days of months of trial enrollment or prior SRS at any time to any lesion to be treated on protocolXx_NEWLINE_xXPrior history of pseudoprogression or radionecrosis from cranial radiotherapyXx_NEWLINE_xXMajor surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before registration; patients who received prior radiotherapy to >= 25% of bone marrow are not eligible independent of when it was receivedXx_NEWLINE_xXAny other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapyXx_NEWLINE_xXRadiation oncology consultation at enrolling site to confirm that disease can be encompassed in a radiotherapy field =< 56 days prior to registration\r\n* NOTE: Radiotherapy quality assurance rapid review must be performed before the first fraction of radiation therapy (RT) is administered; if RT constraints cannot be met, the patient will be removed from the protocol prior to treatmentXx_NEWLINE_xXPlanning to undergo standard preoperative radiotherapyXx_NEWLINE_xXPatient received radiotherapy, surgery, chemotherapy, or an investigational therapy within 2 weeks prior to study entryXx_NEWLINE_xXPrior radiotherapy that precludes the proposed treatment with hypofractionated radiotherapyXx_NEWLINE_xXPatients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy; localized radiotherapy to an area not compromising bone marrow function does not applyXx_NEWLINE_xXPatient received radiotherapy within 2 weeks prior to the first dose of study treatment except localized radiation therapy for symptomatic bone metastasisXx_NEWLINE_xXHas received external radiotherapy within the last 4 weeks prior to start of study treatmentXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic therapies within the following time frame:\r\n* Any prior treatment with capmatinib, crizotinib, or any other cMET or HGF inhibitor\r\n* Thoracic radiotherapy to lung fields =< 4 weeks prior to starting capmatinib; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting capmatinib; palliative radiotherapy for bone lesions =< 2 weeks prior to starting capmatinib is allowed\r\n* Receipt of any anticancer or investigational agent within 4 weeks or =< 5 half-lives of the agent (whichever is longer) prior to the first dose of capmatinib; if previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before the first dose of capmatinibXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic therapies within the following time frame:\r\n* Any prior treatment with ceritinib\r\n* Radiotherapy to lung fields =< 4 weeks prior to starting ceritinib; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting ceritinib; palliative radiotherapy for bone lesions =< 2 weeks prior to starting ceritinib is allowed\r\n* Receipt of any cytotoxic chemotherapy, biologic agent, or investigational agent within 4 weeks prior to the first dose of study drug (within 6 weeks for nitrosoureas, mitomycin C or liposomal doxorubicin)Xx_NEWLINE_xXNo prior radiotherapy to the prostate or lower pelvisXx_NEWLINE_xXPHASE I: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstratedXx_NEWLINE_xXPHASE II: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstratedXx_NEWLINE_xXSystemic anti-neoplastic therapies within 4 weeks prior to the initiation of investigational treatment, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and immunotherapy;Xx_NEWLINE_xXPalliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study treatment;Xx_NEWLINE_xXPrior courses of TSEBT (Note: localized skin-directed radiotherapy is allowed if administered at least 4 weeks prior to initiation on study).Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the studyXx_NEWLINE_xXAny prior chemotherapy, surgery, or radiotherapy for EACXx_NEWLINE_xXRadical radiotherapy to the thorax with curative intent within 28 days of initiation of study drug treatment; palliative radiotherapy for bone lesions outside of the thorax or brain within 14 days of the first dose of study treatment; palliative radiotherapy to the brain or thorax within 28 days of the first dose of study drug treatmentXx_NEWLINE_xXPathologically proven recurrent or second-primary head-and-neck cancer receiving prior radiotherapy with or without chemotherapyXx_NEWLINE_xXPrior radiotherapy to a dose of >= 50 GyXx_NEWLINE_xXHave received NO radiotherapy within 14 days prior to receiving study drugXx_NEWLINE_xXPatient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowedXx_NEWLINE_xXPrior radiotherapy is allowedXx_NEWLINE_xXMajor surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before randomization; Note: no washout required for single dose Gamma Knife radiationXx_NEWLINE_xXReceived prior hemibody external radiotherapyXx_NEWLINE_xXSubjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excludedXx_NEWLINE_xXPrior radiotherapy to any portion of the abdominal cavity or pelvisXx_NEWLINE_xXAny contraindication to external beam radiotherapyXx_NEWLINE_xXPrior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fieldsXx_NEWLINE_xXRadiotherapy within 14 days before enrollmentXx_NEWLINE_xXGreater than or equal to 2 weeks must have elapsed for local palliative radiotherapy (re-irradiation for progressive disease or upfront radiation therapy [RT] at initial diagnosis) and enrollment on study for stratum II; at least 24 weeks must have elapsed if patient received craniospinal radiotherapy due to any other prior malignanciesXx_NEWLINE_xXNo chemotherapy or radiotherapy within the past 28 days and patients must have recovered any acute toxicity associated with their most recent previous treatmentXx_NEWLINE_xXPrior abdominal radiotherapyXx_NEWLINE_xXAny radiotherapy within 2 weeks of registrationXx_NEWLINE_xXThere must be an interval of at least 12 weeks from the completion of radiotherapy to study registration except if there is unequivocal evidence for tumor recurrence per Response Assessment in Neuro-Oncology (RANO) criteria; when the interval is less than 12 weeks from the completion of radiotherapy, the use of positron emission tomography (PET) scan is allowed to differentiate between evidence of tumor recurrence and pseudoprogressionXx_NEWLINE_xXEligible patients should not have had previous pelvic radiotherapy, chemotherapy or surgery for prostate cancerXx_NEWLINE_xXPrior radiotherapy for pancreatic cancerXx_NEWLINE_xXPatient is NOT receiving any other anti-cancer agents or radiotherapy at the time of study entryXx_NEWLINE_xXPrimary lung cancer or metastatic disease to the lungs to be treated with either conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic ablative radiotherapy (SABR)Xx_NEWLINE_xXPrior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fieldsXx_NEWLINE_xXPresence of an index lesion >= 1 cm amenable to hypofractionated radiotherapyXx_NEWLINE_xXA history of prior radiotherapy that precludes delivery of hypofractionated radiotherapyXx_NEWLINE_xXRadiotherapy to the target lesion within the past 3 months prior to baseline imagingXx_NEWLINE_xXPrior pelvic radiotherapyXx_NEWLINE_xXPatient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowedXx_NEWLINE_xXPatients who have received prior radiotherapy at or adjacent to the primary tumor bedXx_NEWLINE_xXPatients who have had radiotherapy =< 4 weeks prior to starting study drug, or =< 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g., for analgesic purpose or for lytic lesions at risk of fracture)Xx_NEWLINE_xXPatients must be >= 4 weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 toxicity or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy fieldXx_NEWLINE_xXPrior radiotherapy to doses >= 45 Gy to the area of recurrence, >= 6 months prior to enrollmentXx_NEWLINE_xXRadiation within 4 weeks of study enrollment; radiotherapy not permitted while on study; exception: palliative radiotherapy of metastasis in extremities is allowed, but such lesions cannot be used as target or non-target lesionsXx_NEWLINE_xXAn interval of >= 2 months since completion of fractionated radiotherapyXx_NEWLINE_xXA history of previously treated brain metastases is allowed, provided that at least 14 days have lapsed between radiation and initiation of MK-3475; any lesion present at the time of whole-brain radiotherapy (WBRT) or included in the stereotactic radiotherapy field (or within 2mm of the treated lesion) will NOT be considered evaluable unless it is new or documented to have progressed since treatmentXx_NEWLINE_xXNo prior radiotherapy to the brainXx_NEWLINE_xXNo prior treatment (chemotherapy, biological therapy, or radiotherapy) for resectable pancreatic cancerXx_NEWLINE_xXIf a cancer survivor, the patient received prior systemic chemotherapy or radiotherapyXx_NEWLINE_xXPatients must be recovered from any toxicity from all prior chemotherapy, immunotherapy, or radiotherapy and be at least 14 days past the date of their last treatmentXx_NEWLINE_xXPrior use of radiotherapy or investigational agents for pancreatic cancerXx_NEWLINE_xXPatients with any prior chemotherapy or radiotherapy for pelvic malignancyXx_NEWLINE_xXPrior radiotherapy to the upper abdomen or radioembolization of the liverXx_NEWLINE_xXContraindication to receiving radiotherapy or TACEXx_NEWLINE_xXPatients may not be receiving any other concurrent chemotherapy, immunotherapy, or radiotherapyXx_NEWLINE_xXPatients who have had prior chemotherapy or radiotherapy for the treatment of pancreas cancerXx_NEWLINE_xXPrior whole brain radiotherapyXx_NEWLINE_xXPrior chemotherapy or radiotherapy for colorectal cancerXx_NEWLINE_xXRadiotherapy to any site for any reason within 28 days prior to study entryXx_NEWLINE_xXPatients must have completed any radiotherapy four weeks prior to study entry, 0-2 weeks for local palliative radiotherapy (XRT) (small port)Xx_NEWLINE_xXPredominance of disease that is amenable to radiotherapyXx_NEWLINE_xXPatients with a history of non-breast malignancies are eligible as long as they have not received prior radiotherapy to the thoracic region, and have a greater than 2 year interval without evidence of recurrenceXx_NEWLINE_xXCompleted all prior therapies (immunosuppressive medications, antineoplastic therapy, vaccination, immunotherapy, chemotherapy, radiotherapy, major surgery, etc) >4 weeks prior to the first study dose of medication (alemtuzumab ? 6 months).Xx_NEWLINE_xXPatients may not receive concurrent chemotherapy, radiotherapy or immunotherapy, nor have received any investigational agents within 7 days prior to drug sensitivity screeningXx_NEWLINE_xXFit to receive chemotherapy and radiotherapy with curative intent.Xx_NEWLINE_xXPatients will be excluded if they have had prior whole brain radiotherapy (WBRT) or prophylactic cranial irradiation (PCI); prior SRS or gamma knife radiosurgery to 1-3 metastases with minimum of (6) weeks to the most recent scan are allowed on protocolXx_NEWLINE_xXPatients must begin partial brain radiotherapy and temozolomide chemotherapy no sooner than 2 weeks and no later than 6 weeks from the surgery in which pathology was confirmed; if a patient elects to have a second surgery to obtain further resection, they will remain eligible for treatment as long as no treatment has been initiated prior to this surgery; in this case, initiation of treatment must begin within 2 to 6 weeks from the last surgery; tissue collection is preferred but not mandatory; patients may have radiotherapy administered at outside facilities; radiotherapy must be given within 2 days of lapatinib initiation and by external beam to a partial brain field in daily fractions of 2.0 Gy, to a planned total dose to the tumor of 60.0 Gy; stereotactic radiosurgery and brachytherapy will not be allowedXx_NEWLINE_xXPatients who received previous radiotherapy to the brainXx_NEWLINE_xXPrior radiotherapy to the pelvis (or abdomen if para-aortic nodes are involved)Xx_NEWLINE_xXPatients must be >= 4 weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field; patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 weeks (wks), whichever is shorter, from the last day of treatment; continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotropin-releasing hormone [GnRH] agonist), ovarian, or breast cancer are not exclusionaryXx_NEWLINE_xXThe patient must have undergone prior external beam radiotherapy to a dose of 54-60 Gy to the brain stem; at least 4 weeks but no more than 14 weeks must have elapsed from the completion of radiotherapyXx_NEWLINE_xXSubjects with recurrent or progressive glioma who have failed standard therapy with surgery and/or radiation for whom local therapy has been requested by the neuro-oncologist. This treatment will be offered as an option for those patients where neither surgery or repeat radiotherapy is advised by the multidisciplinary team. OR Patients with metastatic brain cancer that has progressed despite prior radiotherapy and local therapy is requested by the oncologist. This treatment will be offered as an option for those patients where surgery is not indicated and discussed with the potential options for repeat radiotherapy or salvage radiosurgery by the multidisciplinary team.Xx_NEWLINE_xXPatients may not have previously been treated with > 1 course of radiotherapy to the brainXx_NEWLINE_xXPatients must have progression of disease after radiotherapy (including patients that undergo surgery for recurrent disease and are rendered no evidence of disease [NED]); this includes recurrent glioblastoma multiforme (GBM) after receiving all standard first-line treatment, including surgery (if feasible due to neurosurgical and neuro-anatomical considerations) and adjuvant radiotherapy +/- chemotherapyXx_NEWLINE_xXParticipants who have had any prior cranial radiotherapyXx_NEWLINE_xXReceived radiotherapy ?14 days prior to the first dose of AP32788 of study drug.Xx_NEWLINE_xXRadiotherapy within the 2 weeks prior to initiation of treatmentXx_NEWLINE_xXRadiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor massXx_NEWLINE_xXAt least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolmentXx_NEWLINE_xXPrior radiotherapy: therapeutic radiotherapy within 4 weeks, or palliative radiotherapy (to non-CNS disease) within 1 weekXx_NEWLINE_xXCandidate for pelvic or pelvic-inguinal radiotherapy and concurrent chemotherapy; patients undergoing preoperative chemoradiotherapy are excludedXx_NEWLINE_xXPatient with any prior chemotherapy or radiotherapy for pelvic malignancyXx_NEWLINE_xXNo prior radiotherapy to the upper abdomenXx_NEWLINE_xXUse of concurrent gemcitabine-based chemotherapy during radiotherapyXx_NEWLINE_xXPatient with any prior chemotherapy or radiotherapy for pelvic malignancyXx_NEWLINE_xXNo prior radiotherapy to the prostate or lower pelvisXx_NEWLINE_xXRadiotherapy within 21 days prior to initiation of study treatmentXx_NEWLINE_xXPrior radiotherapy is allowed, provided at least 2 weeks have elapsed from completion of radiotherapy to initiation of protocol treatmentXx_NEWLINE_xXPrior radiotherapy to the paranasal sinus region or the upper neck (i.e., prior radiotherapy to another disease site is acceptable).Xx_NEWLINE_xXSubject has measurable disease according to RECIST 1.1 within 28 days prior to the first dose of study treatment. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.Xx_NEWLINE_xXSubject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma unless the radiotherapy was completed within28 days prior to start of study treatment. Subject who received palliative radiotherapy to peripheral bone metastases ?14 days prior to start of study treatment and has recovered from all acute toxicities is allowed.Xx_NEWLINE_xXLesions that have had radiotherapy must show subsequent radiographic evidence of increase in size by at least 20% to be deemed a target lesion.Xx_NEWLINE_xXPrevious radiotherapy to the lung or mediastinumXx_NEWLINE_xXMajor surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to ? 25% of bone marrow are not eligible, irrespective of when it was received.Xx_NEWLINE_xXPrior radiotherapy that overlaps with planned radiotherapy portalXx_NEWLINE_xXCompletion of pelvic radiotherapy treatment for this current rectal cancer or any prior pelvic radiotherapy (e.g., prior prostate or cervical cancer therapy).Xx_NEWLINE_xXPrevious treatment with radiotherapy, or immunotherapeutic agents, or receipt of live vaccines in the 4 weeks prior to study drug administration;Xx_NEWLINE_xXThoracic radiotherapy to lung fields ? 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicitiesXx_NEWLINE_xXinterval of ? 3 months following radiotherapy + TMZ;Xx_NEWLINE_xX12 weeks from radiotherapyXx_NEWLINE_xXPrior focal radiotherapy within 3 months of screening.Xx_NEWLINE_xXRadiotherapy within the past 2 weeks prior to date of first administration of study drugXx_NEWLINE_xXPatients must have received prior external beam radiotherapy and temozolomide.Xx_NEWLINE_xXPrior radiotherapyXx_NEWLINE_xXPatients are excluded if they have been treated with whole brain radiotherapy within the prior 3 months.Xx_NEWLINE_xXRadiotherapy ? 2 weeks prior to randomization. Patients must have recovered from all radiotherapy-related toxicities.Xx_NEWLINE_xX\Study entry\ is defined as the date of informed consent. Patients who received investigational therapy (agents that are not FDA approved), monoclonal antibody such as bevacizumab or cetuximab, or who received radiotherapy to the skull, spine, thorax or pelvis within 30 days of entry into the protocol. Patients are permitted to have received palliative radiotherapy to an extremity provided at least 14 days has elapsed since completion of therapy, provided the patient received no more than 10 radiotherapy fractions and a dose no higher than 30 Gy to that site, and provided skull, spine, thorax or pelvis were not in the radiotherapy field.Xx_NEWLINE_xXAt least 4 weeks and recovery from effects of prior surgery, prior radiotherapy, or other therapy with an approved or investigational agentXx_NEWLINE_xXPrevious radiotherapy of the tumor bed (for ACC).Xx_NEWLINE_xXConcurrent radiotherapy or radiotherapy within 4 weeks prior to randomization or previous radiotherapy at the indicator sites (the sites that are to be followed for determination of a response)Xx_NEWLINE_xXPrior cancer therapies not completed within 30 days prior to the first cycle of milataxel; radiotherapy completed less than 30 days prior to study enrollment; patients not recovered from radiation-related toxicities; patients receiving any concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an investigational agent while on-study; patients with greater than 2 prior radiotherapy treatments.Xx_NEWLINE_xXRadiotherapy during study or within 3 weeks of start of study drug. [Palliative radiotherapy will be allowed]Xx_NEWLINE_xXCompleted standard therapy ( at least 3 months of chemotherapy ± radiotherapy )Xx_NEWLINE_xXWithin 120 days of completion of standard therapy (surgery, chemotherapy ± radiotherapy)Xx_NEWLINE_xXCompleted radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entryXx_NEWLINE_xXPrevious radiotherapy to the brain.Xx_NEWLINE_xXPelvic radiotherapy administered within less than 6 months prior to enrollment. Subjects who received radiotherapy ?6 months prior to enrollment must demonstrate no cystoscopic evidence or symptoms of radiation cystitis.Xx_NEWLINE_xXPrior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval.Xx_NEWLINE_xXHas received radiotherapy within the 28 days prior to first dose or within 12 weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control.Xx_NEWLINE_xXPatients receiving any systemic chemotherapy, hormonal therapy or radiotherapy.Xx_NEWLINE_xXRadiotherapy as specified in the protocolXx_NEWLINE_xXHas received prior radiotherapy within 3 weeks of start of study treatmentXx_NEWLINE_xXPatients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatmentXx_NEWLINE_xXConcurrent radiotherapy, radiotherapy within 14 days of first G1T48 dose, previous radiotherapy to the target lesion sites, or prior radiotherapy to > 25% of bone marrowXx_NEWLINE_xXRadiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Patients must have recovered from all radiotherapy-related toxicities.Xx_NEWLINE_xXRadiotherapy or prior systemic chemotherapy within 2 weeksXx_NEWLINE_xXPrior radiotherapy (RT) to current field of CNS disease ? 4 weeksXx_NEWLINE_xXThe patient has not received stereotactic radiotherapy within 7 days prior to initiation of study treatment or whole-brain radiotherapy within 14 days prior to initiation of study treatment.Xx_NEWLINE_xXTreatment with prior radiotherapy within 28 days of initiating study drug; however, if the radiation portal covered =< 10% of the bone marrow reserve, the patient may be enrolled without respect to the end date of radiotherapyXx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed: Hormone-replacement therapy; palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1.Xx_NEWLINE_xXPrior pelvic radiotherapyXx_NEWLINE_xXPatients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap.Xx_NEWLINE_xXPatients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.Xx_NEWLINE_xXPatient has completed radiotherapy within 2 weeks prior to treatment initiation.Xx_NEWLINE_xXPatients must be recovered from any toxicity from all prior chemotherapy, immunotherapy, or radiotherapy and be at least 14 days past the date of their last treatmentXx_NEWLINE_xXRadiotherapy to any site for any reason within 28 days prior to treatmentXx_NEWLINE_xXPrior radiotherapy must be completed >= 14 days prior to randomization with documentation of adequate recovery from associated toxicities to grade =< 1Xx_NEWLINE_xXRadiotherapy within 4 weeks of protocol therapyXx_NEWLINE_xXParticipants who have received any chemotherapy or radiotherapy for previous malignancy are not eligibleXx_NEWLINE_xXRadiotherapy within 14 days prior to first IMP administration.Xx_NEWLINE_xXPatients who have had systemic therapy or radiotherapy within 3 weeks prior to the first dose of study therapyXx_NEWLINE_xXRequirement for systemic chemotherapy: all stages except IA (not bulky disease), if involved field is considered radiotherapy (RT) curativeXx_NEWLINE_xXRadiotherapy (except for palliative reasons) the previous two weeks before.Xx_NEWLINE_xXPrior breast or chest radiotherapy for any indicationXx_NEWLINE_xXSubjects with no previous radiotherapy treatment must have a consultation with a radiation oncologist or providers must have a discussion in the context of Neuro-Oncology Tumor Board within 60 days prior to start of IA/BBBD chemotherapy to determine the need for radiotherapy prior to or after IA/BBBDXx_NEWLINE_xXPatients must have had no prior radiotherapy to tumor-involved sitesXx_NEWLINE_xXPatients must have completed chemotherapy, biological or radiotherapy >= 3 weeks prior to entering the studyXx_NEWLINE_xXPatients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatmentXx_NEWLINE_xXAny prior radiotherapy to the neckXx_NEWLINE_xXPatients who have had radiotherapy within 14 days prior to entering the studyXx_NEWLINE_xXPrevious first line treatment with at least standard dose of radiotherapy (total dose >= 54 Gy) and temozolomideXx_NEWLINE_xXConcomitant radiotherapyXx_NEWLINE_xXParticipant is a candidate for, and agrees to receive conventional external beam radiotherapyXx_NEWLINE_xXPalliative radiotherapy (? 10 fractions) within 2 weeks prior to ScreeningXx_NEWLINE_xXAny other concurrent investigational agent or chemotherapy, radiotherapy, hormonotherapy, or immunotherapy. Exceptions are long-term hormonals for prostate (eg, goserelin) and octreotide for neuroendocrine malignanciesXx_NEWLINE_xXAny other concurrent chemotherapy, radiotherapy, or immunotherapy.Xx_NEWLINE_xXNo prior pelvic radiotherapyXx_NEWLINE_xXNo prior cranial radiotherapy will be permittedXx_NEWLINE_xXPrior cranial radiotherapyXx_NEWLINE_xXSubjects must have recovered from all toxicity associated with previous chemotherapy,\n             targeted therapy, or radiotherapyXx_NEWLINE_xXPatients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), or ipilimumab before entering the studyXx_NEWLINE_xXHave had chemotherapy or radiotherapy within 4 weeks prior to entering the studyXx_NEWLINE_xXNo prior chemotherapy or radiotherapy for this malignancyXx_NEWLINE_xXPrior neck radiotherapy that would preclude re-irradiationXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the studyXx_NEWLINE_xXSystemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of CPI-0610Xx_NEWLINE_xXSubjects who have received radiotherapy to tumor lesions that would be chosen as target lesions (measurable disease) within 4 weeks before the start of treatment, except if there is objective evidence of progression of the lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the prior radiotherapy and the screening CT or magnetic resonance imaging (MRI) scan; palliative radiotherapy to non-target lesions is allowed at the investigator’s discretionXx_NEWLINE_xXPrevious radiotherapy to the lesion(s) of interestXx_NEWLINE_xXRadiotherapy within 4 weeks prior to entering the studyXx_NEWLINE_xXThe disease must be considered to be potentially curable by combined radiotherapy and cisplatin based chemotherapyXx_NEWLINE_xXPrior chemotherapy or radiotherapy for the diagnosis of GBM or for cancers of the head and neckXx_NEWLINE_xXPrevious radiotherapy (XRT) or chemotherapyXx_NEWLINE_xXPatients may have had prior radiotherapy for metastatic disease as long as it was > 4 weeks prior to registration and the patient has recovered from adverse events associated with the radiotherapyXx_NEWLINE_xXPHASE II: Patients may have had prior radiotherapy for metastatic disease as long as it was > 4 weeks prior to randomization and the patient has recovered from adverse events associated with the radiotherapyXx_NEWLINE_xXPrior full field radiotherapy < 4 weeks or limited field radiotherapy < 2 weeks prior to first study drug administrationXx_NEWLINE_xXPatients who have received radiotherapy =< 4 weeks prior to starting study drugs, with exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =< 1 and/or from whom >= 30% of the bone marrow was irradiatedXx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapyXx_NEWLINE_xXPatients who have had prior chemotherapy, radiotherapy, or surgery with curative intent for HNSCCXx_NEWLINE_xXPatients must not be receiving any other concurrent therapy considered to be investigational; patients must not be planning to receive any radiotherapy (except localized radiation for palliative care); patients must not be planning to receive any concurrent chemotherapy, immunotherapy, radiotherapy or other treatment with curative intentXx_NEWLINE_xXPatients with para-aortic nodal disease or who require extended field radiotherapy beyond the pelvisXx_NEWLINE_xXNo prior cytotoxic chemotherapy, radiotherapy, immunotherapy, or radioimmunotherapyXx_NEWLINE_xXRadiation oncology consultation to confirm that disease can be encompassed in a radiotherapy field within 56 days prior to step 2 registrationXx_NEWLINE_xXPrior cytotoxic chemotherapy or radiotherapy for this lymphomaXx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPrior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fieldsXx_NEWLINE_xXResidual areas of limited disease should receive radiotherapy following and not prior to transplantationXx_NEWLINE_xXParticipant treated with any prior systemic therapy for myeloma; treatment by localized radiotherapy is not an exclusion criterion if an interval of at least 7 days between the end of radiotherapy and initiation of protocol therapy is observed; intervals of less than 7 days between radiotherapy and initiation of protocol therapy will be considered on a case by case basis with the lead principal investigator (PI), provided toxicity is not a concern; similarly, the dose of corticosteroids received by the participant as part of initial therapy for myeloma should not exceed the equivalent of 160 mg of dexamethasone over a two-week period before initiation of protocol therapyXx_NEWLINE_xXReceived prior radiotherapy to any portion of the abdominal cavity or pelvis.Xx_NEWLINE_xXCurrent or prior pelvic external beam radiotherapy within 5 years of entryXx_NEWLINE_xXPrevious stereotactic or highly conformal radiotherapy within 3 weeks before the start of dosing for this study. Note the stereotactic radiotherapy field must not have included the brain index lesion(s)Xx_NEWLINE_xXPatients receiving concurrent immunotherapy, or radiotherapyXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excludedXx_NEWLINE_xXPrior radium-223 dichloride or hemibody external radiotherapyXx_NEWLINE_xXRadiotherapy within 7 days of study treatmentXx_NEWLINE_xXThe participant received radiotherapy within 14 days prior to randomization.Xx_NEWLINE_xXParticipants with prior mediastinal or thoracic radiotherapy. Prior tangential RT to prior breast cancer is acceptable.Xx_NEWLINE_xXRadiotherapy within 14 days of study treatmentXx_NEWLINE_xXSubjects who received palliative radiotherapy ?2 weeks of study drug initiation.Xx_NEWLINE_xXPrevious first line therapy with at least radiotherapy and temozolomide.Xx_NEWLINE_xXAt least 4 weeks after surgery or radiotherapyXx_NEWLINE_xXAt least 3 weeks (21 days) must have passed since the completion of adjuvant chemotherapy or radiotherapyXx_NEWLINE_xXPatients must not have received prior chemotherapy, radiotherapy, or antibody therapy for lymphomaXx_NEWLINE_xXPatient has completed adjuvant radiotherapy (if indicated) prior to screeningXx_NEWLINE_xXPatient has not recovered from clinical and laboratory acute toxicities of chemotherapy, radiotherapy and surgeryXx_NEWLINE_xXFor participants who are ineligible for auto-SCT, has received at least ?2 lines of prior therapy and has failed to respond to or relapsed after their last line of treatment. For participants who received consolidative local radiotherapy after systemic therapy, local radiotherapy will not be considered as a separate line of treatment.Xx_NEWLINE_xXRadiotherapy within 14 days of randomizationXx_NEWLINE_xXRadiotherapy within 2 weeks prior to study day 1.Xx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis within the last three years are excluded; prior vaginal brachytherapy is allowed; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than two years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXAny previous pelvic radiotherapyXx_NEWLINE_xXCompletion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollmentXx_NEWLINE_xXPatients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.Xx_NEWLINE_xXCNS prophylaxis treatment must be stopped > 1 week prior to CTL019 infusion (e.g. intrathecal methotrexate) f. Radiotherapy:Xx_NEWLINE_xXRadiotherapy within the last 28 days prior to the first RO6958688 infusion with the exception of limited-field palliative radiotherapy.Xx_NEWLINE_xXSerious medical co-morbidities precluding radiotherapyXx_NEWLINE_xXPatients must have one of the following biopsy proven gynecological cancer and a decision to treat with radiotherapy and concurrent cisplatin chemotherapy (RT-CT)\r\n* Newly diagnosed epithelial carcinoma of the cervix, cT1B-3B, N0/1, M0/1\r\n** Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control\r\n* Newly diagnosed epithelial carcinoma of the upper 1/3 vagina, T1-3, N0/1, M0/1\r\n** Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control\r\n* Newly diagnosed endometrioid adenocarcinoma of the uterus, cT1-3, N0/1, M0 unsuitable for primary surgery because of the extent of local disease; these patients are eligible if a prior decision has been made to treat radically with neoadjuvant chemoradiation followed by surgery or further radiotherapy (including brachytherapy) depending on response\r\n* Central pelvis or sidewall recurrence of epithelial carcinoma of the cervix of endometrioid adenocarcinoma of the uterus after previous surgery without previous pelvic radiotherapyXx_NEWLINE_xXPatients who have received any radiotherapy or chemotherapy for their current gynecological cancerXx_NEWLINE_xXPatients who received prior pelvic radiotherapy for any indicationXx_NEWLINE_xXPatients requiring para-aortic radiotherapyXx_NEWLINE_xXPrior radiotherapy within 21 days of screening. Localized radiation therapy to a single site within the last 7 days is acceptable. Concurrent radiotherapy is not permitted.Xx_NEWLINE_xXCompletion of adjuvant radiotherapy according to standard guidelines (e.g. AGO Mamma, NCCN) is strongly recommended. If radiotherapy is not performed the reason for this needs to be documented in the eCRF.Xx_NEWLINE_xXNewly diagnosed participants who are considered appropriate candidates for comprehensive multimodality treatment (involving surgery and/or external beam radiotherapy or chemo radiotherapy).Xx_NEWLINE_xXRadiotherapy within 3 weeks prior to the first dose of lenvatinib.Xx_NEWLINE_xXCompleted palliative radiotherapy within 7 days of the first dose of study medication.Xx_NEWLINE_xXRadiotherapy within 14 days prior to randomization except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomizationXx_NEWLINE_xXPrior radiotherapy is allowedXx_NEWLINE_xXFirst day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy of the brain or spinal cord/cauda equinaXx_NEWLINE_xXTreatment with thoracic or mediastinal radiotherapy within 3 weeks prior to initiation of study drugXx_NEWLINE_xXRadiotherapy within 4 weeks prior to start of study treatment, except as follows:Xx_NEWLINE_xXConcurrent anticancer treatment (for example, cytoreductive therapy, radiotherapy [with the exception of palliative bone-directed radiotherapy, or radiotherapy administered on non-target superficial lesions], immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the investigational agentXx_NEWLINE_xXPrevious pelvic radiotherapy that would prevent prostate/seminal vesicle (SV) irradiationXx_NEWLINE_xXRadiotherapy less than or equal to (<=) 7 days prior to Day 1Xx_NEWLINE_xXPatients must not have MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseasesXx_NEWLINE_xXConcurrent radiotherapy, radiotherapy within 14 days of first trilaciclib (G1T28) doseXx_NEWLINE_xXRadiotherapy, at least 14 days from last local site radiotherapyXx_NEWLINE_xXPrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. For example, patients with prior breast radiotherapy treatments would likely be excluded.Xx_NEWLINE_xXTreatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLCXx_NEWLINE_xXReceipt of any radiotherapy or hormonal therapy for cancer treatment within 30 days prior to first dose of study treatmentXx_NEWLINE_xXAn interval of at least 12 weeks between prior radiotherapy or at least 23 days from prior chemotherapy, 42 days from nitrosoureas and enrollment in this study;Xx_NEWLINE_xXPrior stereotactic radiotherapy;Xx_NEWLINE_xXConcurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)Xx_NEWLINE_xXPrior use of cetuximab in the R/M disease treatment setting (except cetuximab during curative radiotherapy)Xx_NEWLINE_xXPatient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.Xx_NEWLINE_xXPrior treatment with radiotherapy is allowed.Xx_NEWLINE_xXHad chemotherapy or radiotherapy within 4 weeks prior to the first day of Investigational Product (IP) administration.Xx_NEWLINE_xXPrior radiotherapy must be completed at least 4 weeks before patient begins study therapy.Xx_NEWLINE_xXReceiving chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed at least 3 weeks prior to study entry, unless underlying disease is progressing on therapyXx_NEWLINE_xXSystemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of CPI-0610Xx_NEWLINE_xXAny other investigational agent or chemotherapy, radiotherapy, or immunotherapy administered within 4 weeks prior to Screening.Xx_NEWLINE_xXRadiotherapy within 21 days prior to Cycle 1 Day 1. However, if the radiation portal covered ? 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapyXx_NEWLINE_xXNo prior abdominopelvic radiotherapy is allowed except for total body irradiation administered >= 10 years prior; no prior systemic therapy for anal cancerXx_NEWLINE_xXMust not have received systemic antineoplastic therapy, including radiotherapy within 7 days of study treatment, with the exception of hydroxyurea or 6-mercaptopurine for the purposes of cytoreductionXx_NEWLINE_xXPatients may have received prior radiotherapy for symptomatic localized bone lesions or impending spinal cord compression only; radiotherapy must be completed at least 14 days prior to registration and all toxicities must have resolved to =< grade 1Xx_NEWLINE_xXAny prior radiotherapy to the pelvis or abdomenXx_NEWLINE_xXRadiotherapy within 28 days of randomizationXx_NEWLINE_xXSystemic antineoplastic therapy or radiotherapy for other malignant conditions within 12 months before the first dose of any study drug, except for hydroxyurea.Xx_NEWLINE_xXPrevious pelvic radiotherapyXx_NEWLINE_xXPalliative radiotherapy completed =< 7 days from treatment startXx_NEWLINE_xXPatients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy and radiotherapy for localized breast cancer, provided that it was completed more than 2 years prior to registration, and the patient remains free of recurrent or metastatic disease and hormonal therapy has been discontinued; patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPrior therapies: BTK inhibitor, radiotherapy, radiotherapy in the adjuvant setting, or cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.Xx_NEWLINE_xXRadiotherapyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the studyXx_NEWLINE_xXHave undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.Xx_NEWLINE_xXAnticipated use of chemotherapy or radiotherapy not specified in the study protocol while on studyXx_NEWLINE_xXPrevious lung or mediastinal radiotherapyXx_NEWLINE_xXPrior systemic therapy or radiotherapy for MPM; local radiotherapy of noncurative intent (ie, for prevention of instrument-tract recurrence and/or symptom control) is permittedXx_NEWLINE_xXSubjects who have had radiotherapy for pancreatic cancerXx_NEWLINE_xXPrevious first line treatment with at least standard dose of radiotherapy (total dose >= 54 gray [Gy]) and temozolomideXx_NEWLINE_xXPrior history of whole brain radiotherapy (only applicable for AZD3759 BM expansion)Xx_NEWLINE_xXPrior palliative radiotherapy to metastasesXx_NEWLINE_xXPatients that have been treated with any of the following within 4 weeks of starting trial treatment: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy (except LHRH agonists and LHRH antagonists), radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within 2 weeks prior to study treatment).Xx_NEWLINE_xXRadiotherapy within 28 days prior to first dose.Xx_NEWLINE_xXRadiotherapy (except extremities) within 3 months prior to baseline imagingXx_NEWLINE_xXChemotherapy, radiotherapy or immunotherapy must have stopped more than 14 days prior to receiving study drug; however, small field palliative radiotherapy, tyrosine-kinase inhibitor (TKI) therapies, and hormonal therapies are allowedXx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXHistory of radiotherapy for the treatment of melanomaXx_NEWLINE_xXWhole breast radiotherapy is required for patients who underwent breast conserving therapy, including lumpectomy or partial mastectomy. Patients receiving adjuvant radiation therapy must have completed radiotherapy at least 14 days prior to registration for protocol therapy.Xx_NEWLINE_xXParticipant completed all prior radiotherapy with curative intent ? 3 weeks prior to randomizationXx_NEWLINE_xXPrevious radiotherapy within 2 weeks of starting study therapy.Xx_NEWLINE_xXAny disease-directed radiotherapy (except prophylactic cranial irradiation or pre-planned radiotherapy for CNS metastases present prior to start of first-line therapy and non-progressing) after last dose of first-line chemotherapy.Xx_NEWLINE_xXRadiotherapy within 14 days prior to day 1 of protocol therapyXx_NEWLINE_xXRadiotherapy within 2 weeks of the first dose of study drugXx_NEWLINE_xXRadiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor massXx_NEWLINE_xXAnticancer treatment within 28 days before the start of trial treatment, for example cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ-spearing technique), immune therapy, or cytokine therapyXx_NEWLINE_xXTreatment with radiotherapy within 2 weeks prior to the first BTCT4465A (Mosunetuzumab) administrationXx_NEWLINE_xXPrior radiotherapy within 2 weeks of study treatmentXx_NEWLINE_xXThere should also be a minimum of 4 weeks from any prior radiotherapy except for palliative bone directed therapyXx_NEWLINE_xXPatients who have received radiotherapy =< 4 weeks prior to registration, with the exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =< 1 are not eligible for participation\r\n* Note: any lesions treated with radiation therapy cannot be used in disease assessmentXx_NEWLINE_xXConcurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollmentXx_NEWLINE_xXPrior surgery or radiotherapy within 14 days of therapy.Xx_NEWLINE_xXRadiotherapy to the target lesion within the past 3 months prior to baseline imagingXx_NEWLINE_xXPersistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study are not eligibleXx_NEWLINE_xXPatients who are undergoing concomitant radiotherapy are NOT eligible for participationXx_NEWLINE_xXRadiation therapy within 2 weeks of starting the study treatment; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiatedXx_NEWLINE_xXPatient has received any pelvic radiotherapy (including external beam and/or brachytherapy.)Xx_NEWLINE_xXParticipant has had radiotherapy ? 4 weeks or limited field radiation for palliationXx_NEWLINE_xXConcurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)Xx_NEWLINE_xXPatients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy; localized radiotherapy to an area not compromising bone marrow function does not applyXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.Xx_NEWLINE_xXAbility to elect radiotherapy care in conjunction with their physicianXx_NEWLINE_xXPrior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation.Xx_NEWLINE_xXThe participant received radiotherapy within 14 days prior to randomization.Xx_NEWLINE_xXPatient has received no prior treatment with any systemic therapy for the treatment of multiple myeloma\r\n* Prior treatment of hypercalcemia or spinal cord compression with corticosteroids does not disqualify the patient (the dose should not exceed the equivalent of 160 mg of dexamethasone in a 2 week period)\r\n* Patients may receive corticosteroids for the management of their multiple myeloma that should not exceed the equivalent of 160 mg of dexamethasone in a 2 week period and should be stable for at least 7 days prior to the initiation of therapy \r\n* Bisphosphonates are permitted\r\n* Patients treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, are eligible; two weeks must have lapsed since last date of radiotherapy, which is recommended to be a limited field; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completedXx_NEWLINE_xXRadiation therapy within 7 days of enrollment; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 7 days have elapsed since the last date of therapyXx_NEWLINE_xXPrior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to startXx_NEWLINE_xXReceived prior hemibody external radiotherapyXx_NEWLINE_xXPrior therapy with radium-223 or systemic radiotherapy (such as samarium, strontium)Xx_NEWLINE_xXAny radiotherapy must have been completed 2 weeks prior to enrollmentXx_NEWLINE_xXPatients who have received palliative radiotherapy within 4 weeks of study entry.Xx_NEWLINE_xXSubjects who have had previous pelvic radiotherapy or have had chemotherapy or surgery for prostate cancerXx_NEWLINE_xXRadiotherapy < 3 weeks prior to the first planned dose of study treatmentXx_NEWLINE_xXPrevious first line therapy with at least radiotherapy and temozolomideXx_NEWLINE_xXPrior history of pelvic radiotherapyXx_NEWLINE_xXPrior radiotherapy to the region of the body that would result in overlap of RT fields with the current protocol treatmentXx_NEWLINE_xXMust not have received systemic anti-neoplastic therapy, including radiotherapy within 14 days of study treatmentXx_NEWLINE_xXPatients must have received prior radiotherapy and prior temozolomide as treatment for the malignant gliomaXx_NEWLINE_xXPrevious whole brain radiotherapyXx_NEWLINE_xXPrior hemi-body external radiotherapy; subjects who received other types of prior external radiotherapy are allowed provided that bone marrow function is assessed and meets the protocol requirements for hemoglobin, ANC, and plateletsXx_NEWLINE_xXRadiotherapy within 14 days before the first dose of study drug.Xx_NEWLINE_xXPrior radiotherapy to the thoraxXx_NEWLINE_xXParticipants who have had radiotherapy within 4 weeks prior to study entryXx_NEWLINE_xXRadiotherapy to >= 3 sites at the same time within 1 week prior to the first day of treatmentXx_NEWLINE_xXPatients must be >= 4 weeks beyond treatment with any chemotherapy or radiotherapy, and must have recovered to =< grade 2 toxicity for any treatment-limiting toxicity of prior therapy; (exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, ribs, sternum, scapulae, vertebrae or skull were not included in the radiotherapy field); also, patients who have received non-chemotherapeutic biologic agents will need to wait at least five half-lives or four weeks, whichever is shorter, from the last day of treatment; exception: no washout of cetuximab or regorafenib is required for patients who have received prior cetuximab or regorafenib and have recovered from any treatment-related toxicities to grade =< 1Xx_NEWLINE_xXRecurrent or persistent (after the failure of chemotherapy) disease that cannot be treated with surgery or radiotherapy;Xx_NEWLINE_xXPatients must be recovered from any toxicity from all prior chemotherapy, immunotherapy, or radiotherapy and be at least 14 days past the date of their last treatmentXx_NEWLINE_xXParticipants may or may not have received adjuvant radiotherapy, but must be at least 30 days after last dose radiotherapy, with no more than grade 1 residual toxicity at the time of screeningXx_NEWLINE_xXPatients who have received radiotherapy =< 4 weeks prior to registration, with the exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =< 1 and/or from whom >= 30% of the bone marrow was irradiated are not eligible for participationXx_NEWLINE_xXPrior systemic radiotherapy and hemibody external radiotherapyXx_NEWLINE_xXRadiotherapy (except for palliative reasons), targeted therapy, or immunotherapy (except for uveal melanoma) the previous four weeks before study treatment.Xx_NEWLINE_xXPrior systemic radiotherapy and hemibody external radiotherapyXx_NEWLINE_xXNo radiotherapy within 21 days prior to cycle 1 day 1; however, if the radiation portal covered =< 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapyXx_NEWLINE_xXCOHORT B: Prior radiotherapy to the prostate (adjuvant or salvage radiotherapy) is allowedXx_NEWLINE_xXPrevious treatment with radiotherapy and temozolomide (Cohorts 1, 1b and 2 only)Xx_NEWLINE_xXRadiotherapy =< 3 weeks prior to registration, except if to a non-target lesion onlyXx_NEWLINE_xXRadiotherapy within 14 days of study treatment; patient must have recovered from acute effects of radiotherapy to baseline.Xx_NEWLINE_xXat least 8 weeks without tumor progression after any whole brain radiotherapyXx_NEWLINE_xXPrior neck and/or upper thoracic radiotherapy that would cause an overlap of treatment fieldsXx_NEWLINE_xXLast radiotherapy treatment >= 4 weeks prior to starting treatment with this protocol and there must be sites of measurable disease that did not receive radiationXx_NEWLINE_xXThe patient has received therapeutic dose chemotherapy or radiotherapy ? 21 days prior to start of Investigational Product.Xx_NEWLINE_xXBREAST RADIOTHERAPY:Xx_NEWLINE_xXWhole breast radiotherapy is required for participants who underwent breast-conserving therapy, including lumpectomy or partial mastectomy. Participants must have completed radiotherapy at least 14 days prior (but no more than 84 days prior) to study registration.Xx_NEWLINE_xXPrior radiotherapy less than 14 days prior to enrollment, except for WHO Grade 1 4 glioma (radiotherapy is not permitted within 3 months prior to enrollment) and ATC (radiotherapy is not permitted within 7 days prior to enrollment). Treatment-related AEs must have resolved prior to enrollment.Xx_NEWLINE_xXPatient is not a candidate for or declines consolidative thoracic radiotherapy.Xx_NEWLINE_xXPatients receiving any systemic chemotherapy or thoracic radiotherapy within 3 weeks prior to study treatment.Xx_NEWLINE_xXPatients who have had prior abdominal radiotherapyXx_NEWLINE_xXKnown contraindications to radiotherapyXx_NEWLINE_xXPalliative radiotherapy must have been discontinued 1 week prior to treatment in this studyXx_NEWLINE_xXRadiotherapy to >= 3 sites at the same time within 1 week prior to signing consentXx_NEWLINE_xXRadiotherapy, chemotherapy or immunotherapy within 4 weeks, or single fraction of palliative radiotherapy within 14 days of administration of enrollmentXx_NEWLINE_xXPART B: Prior radiotherapy to proposed target lesions is not permitted unless completed more than 4 weeks prior to treatment within the study and that there has been documented progression at these sites; radiotherapy to non-target lesions is permitted within 2 weeks of study entry provided all acute effects of the radiotherapy have resolved to =< grade 1Xx_NEWLINE_xXHas received or is in the process of completing a course of definitive radiotherapy of at least 45 Gray (Gy) with concurrent temozolomide (patient may be registered before completing radiotherapy as long as it is anticipated that s/he will complete at least 45 Gy)Xx_NEWLINE_xXPatients must have received prior radiotherapy for meningioma; patients may have received standard external beam radiation, interstitial brachytherapy, or radiosurgery in any combination; an interval of >= 4 weeks (28 days) must have elapsed from the completion of radiotherapy to study entry and there must be subsequent evidence of tumor progression; patients with prior interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progression disease rather than radiation necrosis based on positron emission tomography (PET), MR-perfusion, MR-spectroscopy, or surgical documentation of disease; if there is any question, investigators should discuss with the MSKCC principal investigator (PI)Xx_NEWLINE_xXLesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.Xx_NEWLINE_xXReceived prior salvage therapy, including radiotherapyXx_NEWLINE_xXChemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drugXx_NEWLINE_xXPatients who have received radiotherapy =< 2 weeks prior to starting treatmentXx_NEWLINE_xXPatients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study; for recent experimental therapies a 28 day period of time must elapse before treatmentXx_NEWLINE_xXNo previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.Xx_NEWLINE_xXPatients must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapyXx_NEWLINE_xXRadiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)Xx_NEWLINE_xXRadiotherapy within 30 days before the first dose of study treatment (within 2 weeks if given as palliation to bone metastases, if recovered from all toxicities)Xx_NEWLINE_xXPrevious chemotherapy, radiotherapy of other treatment for PCXx_NEWLINE_xXPatients who are undergoing concomitant radiotherapy are NOT eligible for participationXx_NEWLINE_xXPatient may have any prior therapy allowed aside from having had prior radiotherapy to the treatment siteXx_NEWLINE_xXPatients who have had external beam radiotherapy, cytotoxic chemotherapy, or oral multikinase inhibitors within 4 weeks prior to study enrollmentXx_NEWLINE_xXPrior systemic anti-cancer treatment and radiotherapy for melanoma; prior surgery for melanoma is allowed.Xx_NEWLINE_xXPrior radiotherapy or biologic therapyXx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXPrior radiotherapy within 4 weeks of the start of study drugXx_NEWLINE_xXPatients who have had previous chemotherapy or radiotherapy for pancreatic adenocarcinoma prior to entering the study.Xx_NEWLINE_xXExposure to chemotherapy, radiotherapy, biologics or investigational agents within 3 weeks prior enrollment in the studyXx_NEWLINE_xXConcomitant antineoplastic therapies including chemotherapy, radiotherapy, or biological agents during the studyXx_NEWLINE_xXHave received antimyeloma treatment, radiotherapy, or any experimental drug or therapy within 2 weeks before the first infusionXx_NEWLINE_xXRecent therapeutic interventions within 3 (chemotherapy/radiotherapy) to 10 weeks (immunotherapy)Xx_NEWLINE_xXNo radiotherapy within 2 weeks: exception: patients may receive palliative low dose radiotherapy (30 Gy or less) for lesions outside the lung at the discretion of the treating physician; palliative radiotherapy could be given before aerosol treatment is started if necessaryXx_NEWLINE_xXRadiotherapy within 14 days before randomization.Xx_NEWLINE_xXThe patient is a candidate for definitive external beam radiotherapy; the patient has had no prior radiotherapy to the region of study; the patient has no inflammatory bowel disease, active collagen vascular or connective tissue disorders, and no other medical or social contraindications to radiotherapy, as determined by a participating radiation oncologistXx_NEWLINE_xXPatient must be a candidate for salvage radiotherapy to the prostate bedXx_NEWLINE_xXTreatment with chemotherapy, radiotherapy, surgery, blood products, or an investigational agent within 3 weeks of trial enrolmentXx_NEWLINE_xXIf radiotherapy is required in a given patient, that patient should be withdrawn from the studyXx_NEWLINE_xXRadiotherapy to any site for any reason =< 14 days prior to randomizationXx_NEWLINE_xXPrior full field radiotherapy =< 4 weeks or limited field radiotherapy =< 2 weeks prior to enrollment; patients must have recovered from all therapy-related toxicities; the site of previous radiotherapy should have evidence of progressive disease if this is the only site of diseaseXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy to the reirradiation target within 4 weeks prior to entering the studyXx_NEWLINE_xXPrior radiotherapy must have been completed at least 2 weeks prior to study entry For Arm M:Xx_NEWLINE_xXNo prior chemotherapy, radiotherapy, or antiangiogenic therapyXx_NEWLINE_xXConcurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. Localized radiotherapy to an area not compromising bone marrow function does not apply. Patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.Xx_NEWLINE_xXPatients treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, are eligible; one week must have lapsed since last date of radiotherapy, which is recommended to be a limited field and from start of protocol therapy; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed and one week have passed since the last date of therapy and from start of protocol therapyXx_NEWLINE_xXPrevious treatment with radiotherapy to the target lesionsXx_NEWLINE_xXPatients who had radiation therapy within 28 days prior to start of study treatment (palliative radiotherapy to bone lesions allowed if completed 2 weeks prior to study treatment start)Xx_NEWLINE_xXPart C: Glioblastoma multiforme that has progressed or recurred after radiotherapy and/or chemotherapyXx_NEWLINE_xXPrior treatment with approximately 60 Gy of radiotherapyXx_NEWLINE_xXPrior cranial radiotherapyXx_NEWLINE_xXRadiotherapy within 21 days prior to cycle 1 day 1; however, if the radiation portal covered =< 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapyXx_NEWLINE_xXWomen with prior radiotherapy to the pelvis or retroperitoneal surgeryXx_NEWLINE_xXWomen who have undergone simple or radical hysterectomy prior to radiotherapyXx_NEWLINE_xXPatients who have received prior treatment with implanted radiotherapy or chemotherapy sources such as wafers of polifeprosan 20 with carmustineXx_NEWLINE_xXE 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of randomization. Participants on biphosphonates prior to study entry.Xx_NEWLINE_xXE 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.Xx_NEWLINE_xXRadiotherapy within 4 weeks prior to first dose of FOLFIRIXx_NEWLINE_xXPrior or concurrent chemotherapy, radiotherapy, or immunotherapy for CLLXx_NEWLINE_xXPatients who require radiotherapy to distant metastases during induction systemic therapy are eligibleXx_NEWLINE_xXPrior radiotherapy delivered to the target regionXx_NEWLINE_xXA minimum of 2 weeks must have elapsed from completion of any prior chemotherapy or radiotherapy or surgery and the start date of study therapyXx_NEWLINE_xXPrior chemotherapy or radiotherapyXx_NEWLINE_xXTREATED PRIMARY - PRIOR RADIOTHERAPY:Xx_NEWLINE_xXRequirement to receive other concurrent chemotherapy (excluding combination therapy defined in original protocol), immunotherapy, radiotherapy, or any other investigational drug while on study. Palliative radiotherapy is allowed provided that:Xx_NEWLINE_xXGlioblastoma disease-specific concerns: Patients must not have received previous or concurrent radiotherapy to the brainXx_NEWLINE_xXHas had radiotherapy within 14 days of randomization. Participants who received radiotherapy >14 days prior to randomization must have completely recovered from any radiotherapy-related AEs/toxicitiesXx_NEWLINE_xXParticipants may have received radiotherapy for palliative purpose, but must not be experiencing > grade 1 treatment related toxicities, and must have completed treatment > 14 days prior to registrationXx_NEWLINE_xXPrior treatment with extended-field radiotherapy within 28 days prior to enrollment or prior treatment with extended-field radiotherapy for evaluating tumor lesions within 14 days prior to enrollment.Xx_NEWLINE_xXPalliative radiotherapy (to bone or soft tissue lesions) must be completed >2 weeks prior to start of study drug.Xx_NEWLINE_xXSubjects receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment;Xx_NEWLINE_xXFollowing surgery, the patient must have received external beam radiotherapy (58-66 Gy in 2 Gy fractions, 5 days per week) with concomitant cisplatin starting within 8 weeks of surgery. A brief delay in the initiation of radiotherapy following 8 weeks post-surgery due to administrative reasons (e.g., start of RT on Mondays) may be permitted by the Medical Monitor. The cumulative dose of cisplatin the subject received must be > 150 mg/m2. Protocol therapy must be initiated within a period of 4-8 weeks (28-56 days) following the end of RT.Xx_NEWLINE_xXPatient may have any prior therapy allowed aside from having had prior radiotherapy to the treatment siteXx_NEWLINE_xXPatient who has had any prior radiotherapy to the treatment site(s)Xx_NEWLINE_xXRadiotherapy within the last 21 days;Xx_NEWLINE_xXPrior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment startXx_NEWLINE_xXAny radiotherapy within 1 week of starting treatment on protocolXx_NEWLINE_xXInterval of at least 12 weeks from prior radiotherapy unless there is either: a) histopathologic confirmation of recurrent tumor, or b) new enhancement on MRI outside of the radiation treatment (RT) fieldXx_NEWLINE_xXPrior surgery or radiotherapy for esophageal or gastroesophageal junction cancerXx_NEWLINE_xXPrior radiotherapy that would overlap the anticipated study treatment fieldsXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.Xx_NEWLINE_xXUse of amifostine or pilocarpine before and during radiotherapy is not allowedXx_NEWLINE_xXPatients will be allowed to participate following single prior CNS treatment with stereotactic radiotherapy whole brain irradiation and stable without steroid requirement for ?2 months or following ?2 prior CNS treatments with stereotactic radiotherapy whole brain irradiation and stable without steroid requirement for ?4 months.Xx_NEWLINE_xXSurgery involving general anesthesia, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to vaccination. Chemotherapy within 3 weeks prior to entering the study. Palliative radiotherapy is allowable. Collection of lumenal tissue for vaccine manufacture must be avoided.Xx_NEWLINE_xXPrior thoracic radiotherapy that would lead to overlap with the current radiation treatment fieldXx_NEWLINE_xXPatients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy; localized radiotherapy to an area not compromising bone marrow function does not applyXx_NEWLINE_xXPrior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted BCNU-wafersXx_NEWLINE_xXNo prior radiotherapy to the brainXx_NEWLINE_xXPatients with a history of pelvic or abdominal radiotherapy;Xx_NEWLINE_xXNo previous radiotherapy or chemotherapy other than corticosteroid therapyXx_NEWLINE_xXRadiotherapy to the target lesions within 3 weeks of start of first dose. Toxicities from radiotherapy must have resolved prior to start of first dose.Xx_NEWLINE_xXPatients who are candidates for curative surgery or radiotherapyXx_NEWLINE_xXRadiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)Xx_NEWLINE_xXNo prior treatment except for local radiation or a short course of steroids for control of symptoms; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXPatient must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.Xx_NEWLINE_xXSubject has received radiotherapy within 1 week prior to the first dose of study drug. If the subject received radiotherapy > 1 week prior to study treatment, the irradiated lesion cannot be the only lesion used for evaluating response.Xx_NEWLINE_xXChemotherapy, radiotherapy, HDAC inhibitors, or other plasma cell directed therapy within 2 weeksXx_NEWLINE_xXHas received and completed a course of pelvic radiotherapy ? 6 months prior to LAR surgery (Day 0).Xx_NEWLINE_xXRadiotherapy within 14 days prior to first dose of study treatmentXx_NEWLINE_xXPrior radiotherapy =< 14 days, or if subjects have not recovered from radiotherapyXx_NEWLINE_xXRadiotherapy within 2 weeks prior to study registration. Subjects must have recovered from all therapy-related toxicities.Xx_NEWLINE_xXPrior radiotherapy to the pelvisXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy to the oropharynx prior to entering the studyXx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXPre- or post-operative radiotherapyXx_NEWLINE_xXPrior palliative radiotherapy to non-central nervous system (CNS) lesions must have been completed at least 2 weeks prior to enrollment; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of enrollment are strongly encouraged to receive palliative radiotherapy prior to enrollmentXx_NEWLINE_xXRadiation therapy (except for localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture): ?4 weeksXx_NEWLINE_xXRadiation therapy (localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture) ?2 weeksXx_NEWLINE_xXHas received radiotherapy within the 28 days prior to randomization, with the exception of palliative radiotherapy to focal lesions for pain or other symptom controlXx_NEWLINE_xXChemotherapy or radiotherapy within 14 days prior to first dose of protocol therapyXx_NEWLINE_xXRadiotherapy within 2 weeksXx_NEWLINE_xX14 days for non-cytotoxic cancer therapies and radiotherapyXx_NEWLINE_xXSubject has received any agent with antitumor activity (other than an EGFR inhibitor, including a T790M inhibitor) including chemotherapy, radiotherapy, immunotherapy, within 14 days prior to the first dose of study drug (palliative radiotherapy is allowed).Xx_NEWLINE_xXAny whole brain radiotherapy (WBRT) was completed at least 2 weeks prior to the first dose of study drug.Xx_NEWLINE_xXPatients with prior history of head and neck radiotherapy (> 40 Gy) with significant areas of anticipated overlapXx_NEWLINE_xXPalliative radiotherapy is allowed up to 2 weeks before the first RO6927005 infusion; palliative 8 Gy radiotherapy is allowed during therapy.Xx_NEWLINE_xXSubjects who have had surgery/radiotherapy within 2 weeks prior to start of studyXx_NEWLINE_xXPatients who have had chemotherapy, biologic therapy or radiotherapy within 3 weeks prior to entering the studyXx_NEWLINE_xXPatients who cannot tolerate thoracic radiotherapy or targeted therapyXx_NEWLINE_xXRadiotherapy within 14 days prior to Baseline.Xx_NEWLINE_xXSubjects who received radiotherapy for DCIS may enrollXx_NEWLINE_xXRadiotherapy within 4 weeks before enrollment.Xx_NEWLINE_xXRadiotherapy within 4 weeks before enrollment.Xx_NEWLINE_xXPrevious radiotherapy to the pelvisXx_NEWLINE_xXTreatment with radiotherapy-response or biological-response modifiersXx_NEWLINE_xXPrior selective internal radiotherapy/hepatic arterial yttrium therapy, at any timeXx_NEWLINE_xXPatients must have completed any previous surgery or radiotherapy >= 4 weeks prior to enrollmentXx_NEWLINE_xXRadiotherapy within 3 weeks prior to start of treatmentXx_NEWLINE_xXPrior external beam radiation therapy completed < 3 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug.Xx_NEWLINE_xXPrior radiotherapy to disease sites is allowed with certain protocol-defined restrictions.Xx_NEWLINE_xXAny major surgery, radiotherapy or immunotherapy within the 4 weeks prior to first dose of study drug, or palliative radiotherapy to a single symptomatic lesion within the 2 weeks prior to first dose of study drugs.Xx_NEWLINE_xXPreviously undergone chemotherapy, brachytherapy, or radiotherapy prior to entering the studyXx_NEWLINE_xXRadiotherapy or chemotherapy ending within 14 days of study enrollmentXx_NEWLINE_xXRadiotherapy within the last 2 months in the area to be treatedXx_NEWLINE_xXSubjects receiving concomitant treatment with radiotherapy or other investigational drugsXx_NEWLINE_xXPrior chemotherapy, radiation for any malignancy in which they received any thoracic radiotherapyXx_NEWLINE_xXPatient must not undergo concomitant radiotherapy, chemotherapy or immunotherapy; patient must not be in concurrent study with other investigational agentsXx_NEWLINE_xXPrevious treatment with cytotoxic chemotherapy, immunotherapy, or radiotherapy are permitted, if the last dose was given at least 4 weeks prior to the first dose of ponatinibXx_NEWLINE_xXRadiotherapy to any site for any reason within 28 days prior to randomization, except for palliative radiotherapy to bone lesions within 14 days prior to randomizationXx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXinterval of at least 3 months following initial radiotherapy and temozolomideXx_NEWLINE_xXPrior focal radiotherapyXx_NEWLINE_xXUnresected tumour prior to chemo-radiotherapy (CRT)Xx_NEWLINE_xXPatients who received radiotherapy within 4 weeks of entryXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must have received a minimum of 54 Gy focal irradiation administered over approximately 42 days prior to enrollment; patients must have recovered from the acute treatment-related toxicities (defined as =< grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPrior palliative or curative radiotherapy must be completed at least 14 days prior to randomizationXx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapyXx_NEWLINE_xXPatients who have had prior abdominal radiotherapyXx_NEWLINE_xXPrior radiotherapy with curative intentXx_NEWLINE_xXPrior chemo-radiotherapy with curative intentXx_NEWLINE_xXLocalised palliative radiotherapy Prior chemotherapy must be > 6 months before screeningXx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatmentXx_NEWLINE_xXLesions that have had radiotherapy must show subsequent radiographic evidence of increased size to be deemed a target lesion.Xx_NEWLINE_xXPatients may have had prior therapy, including radiotherapy (systemic and/or cranial and/or spinal) or chemotherapy; at least 28 days must have elapsed since completion of radiotherapy and 28 days since completion of prior chemotherapy (42 days for nitrosourea chemotherapy)Xx_NEWLINE_xXPatients receiving concomitant radiotherapy or immunotherapyXx_NEWLINE_xXSystemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of CPI-0610Xx_NEWLINE_xXPrior radiotherapy within 2 weeks prior to first dose of study drugXx_NEWLINE_xXPrevious whole brain radiotherapy (WBRT)Xx_NEWLINE_xXChemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug.Xx_NEWLINE_xXPalliative radiotherapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1Xx_NEWLINE_xXPrior radiotherapy to the ipsilateral chest wall for any malignancy.Xx_NEWLINE_xXAn immediate need for palliative radiotherapy or systemic corticosteroid therapy.Xx_NEWLINE_xXDocumented diagnosis of the following: Myelodysplastic syndrome lasting ? 3 months and < 3 years Disease must not be secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseasesXx_NEWLINE_xXLess than three weeks since the last radiotherapy doseXx_NEWLINE_xXTreated with local radiotherapyXx_NEWLINE_xXRadiotherapy: At least 28 days must have elapsed since and radiation therapy.Xx_NEWLINE_xXAt least 2 weeks since prior radiotherapy, endocrine therapy, trastuzumab, or lapatinib, with complete recovery from the effects of these interventionsXx_NEWLINE_xXParticipants who have received radiotherapy less than 2 weeks prior to first dose of study medicationXx_NEWLINE_xXConcurrent cancer chemotherapy, radiotherapy or surgeryXx_NEWLINE_xXRadiotherapy within 28 days prior to first dose.Xx_NEWLINE_xXDiscontinuation of all other therapies (including other investigational drugs, radiotherapy, or chemotherapy) for the treatment of cancer ?4 weeks (?6 weeks if nitrosoureas, ?12 weeks if radiotherapy) before initiation of study treatmentXx_NEWLINE_xXReceived systemic treatment for lymphoma such as chemotherapy, immunotherapy, radiotherapy, investigational agents, or radioimmunotherapy.Xx_NEWLINE_xXSubject has had radiotherapy or surgery within the 4 weeks prior to treatment with ASP4132.Xx_NEWLINE_xXLess than 28 days elapsed from prior treatment with immunotherapy, radiotherapy, or surgery to the time of randomization.Xx_NEWLINE_xXReceived monoclonal antibodies (for any reason), chemotherapy, surgery, investigational therapy, or radiotherapy within 14 days of the first dose of mogamulizumab;Xx_NEWLINE_xXPatients who have had chemotherapy (or so-called ‘targeted’ systemic therapy), large field radiotherapy, or major surgery must wait 4 weeks after completing treatment prior to entering the studyXx_NEWLINE_xXPatients who have had palliative radiotherapy within 3 weeks prior to entering the studyXx_NEWLINE_xXPalliative surgery or radiotherapy.Xx_NEWLINE_xXReceived palliative/focal radiotherapy within 2 weeks of first dose of study treatment.Xx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy for intrahepatic cholangiocarcinomaXx_NEWLINE_xXPrior radiation therapy completed < 3 weeks or single fraction of palliative radiotherapy < 14 days prior to first dose of KPT-330 (selinexor)Xx_NEWLINE_xXRadiotherapy within 14 days before the first dose of study drug.Xx_NEWLINE_xXRadiotherapy within 4 weeks prior to the start of study treatmentXx_NEWLINE_xXRadiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to Day 1 of Cycle 1, except palliative radiotherapy to bone lesions within 7 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXPatients may have received palliative radiotherapy to non-target lesions within 14 days prior to registration provided all radiotherapy related toxicities have resolved to =< grade 1 prior to registration; patients must not have received any major surgery within 28 days prior to registrationXx_NEWLINE_xXRadiotherapy within 14 days before the first dose of study treatment.Xx_NEWLINE_xXPatients treated with local radiotherapy with or without a brief (2 weeks or less) exposure to steroids are eligible; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completedXx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXConcomitant chemotherapy or radiotherapy is not permitted.Xx_NEWLINE_xXimmediately previous cancer chemotherapy, radiotherapy, or immunotherapy; and eligibility for allogeneic HSCT at the time of enrollment.Xx_NEWLINE_xXExtensive prior radiotherapy.Xx_NEWLINE_xXReceived radiotherapy and temozolomide chemotherapyXx_NEWLINE_xXThere must be an interval of at least 12 weeks from the completion of radiotherapy to start of device treatment; when the interval is less than 12 weeks from the completion of radiotherapy, the histological confirmation of progression must be unequivocal per Revised Assessment in Neuro-Oncology (RANO) criteria; the use of positron emission tomography (PET) scan, perfusion imaging, and magnetic resonance (MR) spectroscopy to differentiate between true early progression and pseudoprogression prior to biopsy or resection of probable recurrent tumor is per standard of careXx_NEWLINE_xXPrior radiotherapy to the pelvis or abdomenXx_NEWLINE_xXRadiotherapy (RT) completed within 14 days prior to the first dose of study therapy.Xx_NEWLINE_xXRadiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXAn immediate need for palliative radiotherapy or systemic corticosteroid therapyXx_NEWLINE_xXRadiotherapy within 14 days preceding the first dose of study treatmentXx_NEWLINE_xXPrevious radiotherapy for the treatment of unresectable, locally advanced/recurrent or metastatic breast cancer is not allowed if:\r\n* The last fraction of radiotherapy has been administered within 14 days of first on-study thormbokinetic study\r\n* The patient has not recovered from any resulting acute toxicity (to grade =< 1) prior to first on-study thormbokinetic studyXx_NEWLINE_xXPatients should not have received radiotherapy within 14 days prior to the first dose of orteronelXx_NEWLINE_xXNo prior systemic therapy or radiation therapy active against myeloma lasting more than four weeks duration; any prior therapy must be completed a minimum of 21 days before starting study drugs; enrollment of subjects who require radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapyXx_NEWLINE_xXFocal radiation therapy within 4 weeks before first dose of study treatment, or full spinal radiotherapy within 3 months before first dose of study treatment.Xx_NEWLINE_xXPatients who have had radiotherapy =< 4 weeks prior to starting study drug, or =< 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicitiesXx_NEWLINE_xXRadiotherapy within 4 weeks before start of study treatmentXx_NEWLINE_xXNo concurrent radiotherapy or chemotherapy may be given to the patient during the administration of the study drugXx_NEWLINE_xXTreatment with prior radiotherapy within 21 days prior to first dose of study treatment; however, if the radiation portal covered ? 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy.Xx_NEWLINE_xXPrior pelvic external beam radiotherapy (EBRT)Xx_NEWLINE_xXPrior local radiotherapy is allowed if it is completed at least 4 weeks prior to the first dose of study drug and the subject has evaluable lesions not previously irradiatedXx_NEWLINE_xXPrior chemotherapy or radiotherapy (other than limited, emergent radiotherapy for treatment of eg. spinal cord compromise or threatened airway)Xx_NEWLINE_xXRadiotherapy delivered to non-target lesions within one week prior to starting study treatment or delivered to target lesions that will be followed on the study (NOTE: prior sites of radiation will be recorded)Xx_NEWLINE_xXRadiotherapy within 14 days of study treatmentXx_NEWLINE_xXPatient is receiving concurrent radiation therapy to treat primary disease with curative intent. (Note that palliative radiotherapy is allowed as long as there is no evidence of progressive disease.)Xx_NEWLINE_xXPatients who have had large field radiotherapy must wait 2 weeks prior to entering the studyXx_NEWLINE_xXAt least 4 weeks must have elapsed since prior radiotherapyXx_NEWLINE_xXSurgery (except minor surgeries,e.g., biopsies) or radiotherapyXx_NEWLINE_xXPrior thoracic radiotherapyXx_NEWLINE_xXPrior abdominal radiotherapyXx_NEWLINE_xXAt least 30 days since localized surgery, radiotherapy or chemotherapyXx_NEWLINE_xXAll adverse events of any prior chemotherapy, surgery, or radiotherapy not resolvedXx_NEWLINE_xXLesions that have had radiotherapy must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.Xx_NEWLINE_xXRadiotherapy or systemic therapy within 2 weeks of baselineXx_NEWLINE_xXPatients who have had chemotherapy (other than sorafenib treatment), large field radiotherapy, or major surgery must wait 4 weeks prior to entering the studyXx_NEWLINE_xXPatients who have received radiotherapy within =< 4 weeks prior to registrationXx_NEWLINE_xXPalliative radiotherapy is not permitted throughout the study period;Xx_NEWLINE_xXRadiotherapy to multiple sites or immunotherapy within 14 days of initiation of study drug treatment (localized radiotherapy to a single site at least 7 days before start is permissible)Xx_NEWLINE_xXLast radiotherapy treatment 4 weeks prior to starting treatment with this protocol – with the exception of palliative radiotherapy – and there must be sites of measurable disease that did not receive radiationXx_NEWLINE_xXHas completed any prior radiotherapy ? 4 weeks prior to randomizationXx_NEWLINE_xXRadiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior to randomization; localized radiotherapy to a single site within 7 days prior to randomizationXx_NEWLINE_xXAny major surgery, radiotherapy, or immunotherapy within the last 4 weeks. Limited radiotherapy within the last 2 weeks.Xx_NEWLINE_xXConcomitant chemotherapy or radiotherapy is not permitted.Xx_NEWLINE_xXIf most recent histology shows progression to high grade glioma, patients must have had prior radiotherapy in order to be eligibleXx_NEWLINE_xXPatients may have had treatment (including radiotherapy) for any number of relapses prior to this recurrenceXx_NEWLINE_xXThe participant has completed prior chemotherapy and/or radiotherapy with curative intent at least 3 weeks prior to the administration of the first dose of study therapy. Participants that have received palliative radiation therapy to bony metastases prior to the first dose of study medication are eligibleXx_NEWLINE_xXPatients that start chemotherapy or radiotherapy during the study time (1 month post diagnostic bronchoscopy), will be excluded from the studyXx_NEWLINE_xXPrevious radiotherapy delivered to the upper abdomen.Xx_NEWLINE_xXRequirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except for pain control) or any other investigational drug while on this study.Xx_NEWLINE_xXPatients with advanced or recurrent salivary gland cancer who are not candidates for curative surgery or radiotherapy.Xx_NEWLINE_xXNo prior radiotherapyXx_NEWLINE_xXPatient has completed adjuvant radiotherapy (if indicated) according to the institutional guidelines prior to screeningXx_NEWLINE_xXPatient has not recovered from clinical and laboratory acute toxicities of chemotherapy, radiotherapy and surgeryXx_NEWLINE_xXChemotherapy, radiotherapy, immunotherapy or other medications intended for antitumor activityXx_NEWLINE_xXRadiosurgery or radiotherapy for target lesions within 2 weeks prior to starting trial treatmentXx_NEWLINE_xXAll previous treatment (including surgery, radiotherapy and systemic anti-neoplastic therapy) must have been completed at least three weeks prior to study entry and any acute toxicities must have resolvedXx_NEWLINE_xXA treatment with any other agent with antitumor activity including chemotherapy, radiotherapy, or immunotherapyXx_NEWLINE_xXPalliative radiation treatment (e.g., pain control, bony lesions at risk of fracture) completed =< 2 weeks of starting study treatment; patient will be eligible if palliative radiotherapy is completed > 2 weeks from the start of study treatment and has recovered from radiotherapy toxicitiesXx_NEWLINE_xXAll patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), and surgery, >= 28 days before study entryXx_NEWLINE_xXPatients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy; localized radiotherapy to an area not compromising bone marrow function does not applyXx_NEWLINE_xXPatient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowedXx_NEWLINE_xXRadiotherapy (external beam or CyberKnife) =< 28 days prior to starting study drug, or =< 14 days prior to study registration in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicitiesXx_NEWLINE_xXRadiotherapy for prostate cancer,Xx_NEWLINE_xXPrior cranial radiotherapyXx_NEWLINE_xXPrior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would existXx_NEWLINE_xXPrior chemotherapy or radiotherapy for any brain tumorXx_NEWLINE_xXPrior treatment with thoracic radiotherapy completed > 4 weeks and =< 9 months prior to enrollmentXx_NEWLINE_xXOngoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for this malignancy (Note: hormonal therapy is allowed)Xx_NEWLINE_xXCompleted active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded)Xx_NEWLINE_xXParticipants with a history of pelvic irradiation; or chemotherapy or radiotherapy within the preceding 14 daysXx_NEWLINE_xXReceived external beam radiotherapy within 4 weeks prior to registrationXx_NEWLINE_xXPrior radiotherapy is allowed, provided at least 2 weeks have elapsed from completion of radiotherapy to initiation of protocol treatmentXx_NEWLINE_xXCOHORT A SPECIFIC INCLUSION: At least 12 weeks elapsed since prior radiotherapyXx_NEWLINE_xXRadiotherapy less than 3 weeks before the first dose of study treatment. If prior radiotherapy occurred <4 to 6 weeks before study start, as radiated lesions cannot be reliably assessed by fluorodeoxyglucose-positron emission tomography (FDG-PET), nonradiated target lesions are required for eligibility, and prior radiotherapy information must be submitted to the IRC.Xx_NEWLINE_xXRecurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy;Xx_NEWLINE_xXRadiotherapy to the target lesions within 3 months prior lymphodepleting chemotherapy. A lesion with unequivocal progression may be considered a target lesion. There is no washout period for palliative radiation to non-target lesions.Xx_NEWLINE_xXRadiotherapy for RCC within 14 days of first study treatment with the exception of a single fraction of radiation administered for palliation of symptomsXx_NEWLINE_xXPATIENT ONLY: Patients must be within 1 month of initiating or having undergone any type of cancer treatment (i.e., surgery, radiotherapy, chemotherapy)Xx_NEWLINE_xXHaving finished radiotherapy at least two months agoXx_NEWLINE_xXPrior surgery or radiotherapy (RT) within 2 weeks of study entryXx_NEWLINE_xXReceiving chemotherapy or radiotherapy at the time of study enrollment. Anti-her2 directed therapy is not exclusionary.Xx_NEWLINE_xXPrior surgery or radiotherapy (RT) within 2 weeks of study entryXx_NEWLINE_xXWhole-brain radiotherapy (WBRT) < 14 days from the anticipated start of nintedanib/placebo administrationXx_NEWLINE_xXPrior breast, chest or pelvic radiotherapyXx_NEWLINE_xXNo concurrent use of chemotherapy or radiotherapy (radiotherapy should be completed at least 4 weeks from study entry)Xx_NEWLINE_xXWill receive radiotherapy of cranium within one week prior to or during the studyXx_NEWLINE_xXPATIENTS ONLY: Diagnosed with a primary glioma and going to receive at least 4 weeks of radiotherapy with at least 20 fractionsXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXDiagnosis of cancer (any stage) for which active treatment (e.g., surgery, chemotherapy, and/or radiotherapy) has been completed within 2 months to 2 yearsXx_NEWLINE_xXUndergoing cancer treatment (chemotherapy, radiotherapy, and/or immunotherapy)Xx_NEWLINE_xXMust have received and completed radiotherapy with or without chemotherapy for head and neck cancer; time from completion of radiotherapy to registration must be at least 3 months and up to a maximum of 1 yearXx_NEWLINE_xXPelvic radiotherapy administered within less than 6 months prior to enrollment. Subjects who received radiotherapy ? 6 months prior to enrollment must demonstrate no cystoscopic evidence or symptoms of radiation cystitis.Xx_NEWLINE_xXRadiotherapy within 28 days and abdominal/pelvic radiotherapy within 60 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXDiagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms;Xx_NEWLINE_xXPatient has received prior radiotherapy to the involved breastXx_NEWLINE_xXParticipants who have had prior cHL-directed chemotherapy or radiotherapyXx_NEWLINE_xXUtilization of amifostine during radiotherapyXx_NEWLINE_xXPatient must not have history of prior cranial radiotherapyXx_NEWLINE_xXSubjects who have received radiotherapy to the pelvis and/or sternum within one year of first Investigational Product administrationXx_NEWLINE_xXscheduled to begin chemotherapy or radiotherapyXx_NEWLINE_xXPrior radiotherapy to the pelvis or prostateXx_NEWLINE_xXWomen who have undergone prior radiotherapy to the chest wall and/or breastXx_NEWLINE_xXReceiving radiotherapy or chemoradiationXx_NEWLINE_xXUndergoing induction or neoadjuvant chemotherapy prior to radiotherapyXx_NEWLINE_xXHigh risk for poor compliance with radiotherapy, humidification, or follow-up as assessed by the investigatorXx_NEWLINE_xXPrior chemotherapy for SCCHN and/or radiotherapy to the region of the study cancer orXx_NEWLINE_xXBe receiving concurrent radiotherapy or interferon.Xx_NEWLINE_xXPrior chemotherapy or radiotherapyXx_NEWLINE_xXCancer diagnosis or received treatment (chemotherapy or radiotherapy) for malignancy within the previous 6 monthsXx_NEWLINE_xXPatient has received or is scheduled to receive total body irradiation, total nodal irradiation, upper abdomen radiotherapy, half or upper body irradiation, radiotherapy of the cranium, craniospinal regions, head and neck, lower thorax region or the pelvis within 1 week prior to study entry (Day 1) or within 120 h after start of chemotherapy administration on Day 1.Xx_NEWLINE_xXPatients may be enrolled between 3 months and 5 years AFTER completion of curative-intent therapy (including surgery, radiotherapy, and/or chemotherapy)Xx_NEWLINE_xXPrior cancer chemotherapy or radiotherapyXx_NEWLINE_xXPrior malignancy in which they received any thoracic radiotherapy unless the treating physician considers it unlikely to impact the clinical outcome of the patientXx_NEWLINE_xXMedical contraindication to receipt of radiotherapyXx_NEWLINE_xXPrevious brain radiotherapyXx_NEWLINE_xXRadiotherapy within 4 weeks or less prior to starting first veledimex doseXx_NEWLINE_xXPrior radiotherapy to the upper abdomen/liverXx_NEWLINE_xXMust have completed radiotherapy at least 12 months prior to entryXx_NEWLINE_xXPatients who have received surgery alone or radiotherapy alone as definitive local therapyXx_NEWLINE_xXNo previous radiotherapy or systemic treatment for SCCHNXx_NEWLINE_xXPrior radiotherapy that overlaps with radiation fieldsXx_NEWLINE_xXRadiotherapy within 14 days of first study treatment with the exception of a single fraction of radiation administered for palliation of symptomsXx_NEWLINE_xXRadiotherapy treatment prior to the first veledimex dose:Xx_NEWLINE_xXParticipants may or may not have received adjuvant radiotherapy, but must be at least 30 days after last dose radiotherapy, with no more than grade 1 residual toxicity at the time of screeningXx_NEWLINE_xXSubject receiving radiotherapy alone as treatment for his/her haematologic malignancy.Xx_NEWLINE_xXWillingness to undergo pelvic radiotherapyXx_NEWLINE_xXConcurrent radiotherapy prior to the performance of both CMR studies, however consolidative radiotherapy after the completion of DOX and after the acquisition of the second CMR study is acceptableXx_NEWLINE_xXNo prior malignancy treated with chemotherapy or mediastinal radiotherapyXx_NEWLINE_xXWillingness to undergo radiotherapy.Xx_NEWLINE_xXNo gross disease visible on imaging at the start of radiotherapyXx_NEWLINE_xXSubjects who had prior chemotherapy or radiotherapy for pancreatic adenocarcinoma cannot participate in the studyXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPatient has received prior chemotherapy or radiotherapy for this cancerXx_NEWLINE_xXHistory of hemibody external radiotherapy as assessed by medical record reviewXx_NEWLINE_xXParticipants who have had surgery, chemotherapy, or radiotherapy of the sacrum prior to entering the studyXx_NEWLINE_xXPrior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least 2 weeks prior to infusion of radiolabeled antibodyXx_NEWLINE_xXNo prior pelvic radiotherapyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 12 months of the study for other diagnoses not related to prostate cancerXx_NEWLINE_xXNo gross disease visible on imaging at the start of radiotherapyXx_NEWLINE_xXPatient must have been valuated by a thoracic radiation oncologist within the past 4 weeks and deemed an appropriate candidate for stereotactic ablative radiotherapy (SABR)Xx_NEWLINE_xXParticipants may have had prior therapy for the primary brain tumor, including surgery, radiotherapy or chemotherapyXx_NEWLINE_xXNo prior history of breast radiotherapy that will prevent the use of radiotherapy for the present DCISXx_NEWLINE_xXPrior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy)Xx_NEWLINE_xXRadiotherapy to the abdomen or pelvis within 6 months of the screening visitXx_NEWLINE_xXPatient must not have received craniospinal radiotherapy or involved field radiotherapy to the local tumor (and/or tumor designated as “measurable” for protocol purposes) =< 24 weeks prior to study entry; focal radiation to areas of symptomatic metastatic disease must not be given within 14 days of study entryXx_NEWLINE_xXAny major radiotherapy, tumor-directed systemic or immunotherapy within the last 4 weeks for any indicationXx_NEWLINE_xXHas received prior radiotherapy within 2 weeks of start of study treatment for any other condition.Xx_NEWLINE_xXInterval of at least 6 months from the completion of any prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:\r\n* New areas of tumor outside the original radiotherapy fields as determined by the investigator, or\r\n* Histologic confirmation of tumor through biopsy or resection, or\r\n* Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than pseudo progression or radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registrationXx_NEWLINE_xXSubjects may not have received prior radiotherapy to the index lesion within 4 weeksXx_NEWLINE_xXPrior chemotherapy or radiotherapy within the last three yearsXx_NEWLINE_xXAny prior radiotherapy to the head and neck regionXx_NEWLINE_xXPrior history of pelvic radiotherapyXx_NEWLINE_xXPatients who have received previous treatment (chemotherapy or radiotherapy) for any brain tumor (primary or metastatic)Xx_NEWLINE_xXPatients with thoracic disease to be treated using radiotherapy will be eligible for this studyXx_NEWLINE_xXPast history of pelvic radiotherapyXx_NEWLINE_xXSubjects who have had chemotherapy or radiotherapy within 1 week of entering the studyXx_NEWLINE_xXRadiotherapy, chemotherapy or any investigational agent within the previous 2 weeks of administrating 18F-PEG6-IPQA for PET/CT imagingXx_NEWLINE_xXPatient has received prior chemotherapy or radiotherapy for this cancerXx_NEWLINE_xXDiscontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL >= 3 weeks before initiation of study treatmentXx_NEWLINE_xXRadiotherapy of brain tumor within 3 months before enrollmentXx_NEWLINE_xXParticipants must have no immediate requirements for chemotherapy, radiotherapy or hormonal therapyXx_NEWLINE_xXMust have received at least 1 prior approved immunotherapy or chemotherapy; however, not within 28 days of the initial dose of study drug. May have received prior radiotherapy for their malignancy.Xx_NEWLINE_xXAny major radiotherapy, or immunotherapy within the last four weeks; use of erythropoietin replacement or bisphosphonates is considered supportive care and their use is permittedXx_NEWLINE_xXA plan to treat with radiotherapyXx_NEWLINE_xXPalliative radiotherapy within 2 weeks prior to first dose of study drug treatment in Cycle 1Xx_NEWLINE_xXRadiotherapy less than 3 weeks before the first dose of study treatment.Xx_NEWLINE_xXsubjects with any contraindication to pelvic radiotherapy including, but not limited to, previous pelvic radiotherapy or brachytherapyXx_NEWLINE_xXRadiotherapy to the bone marrow within 6 weeks prior to enrollment OR within3 months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least 60% of the pelvis was received; within 2 weeks prior to enrollment if local palliative radiotherapy was received.Xx_NEWLINE_xX